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Paragonimiasis is a parasitic disease caused by Paragonimus 
trematodes, commonly known as lung flukes. Humans become 
infected by eating raw or undercooked crayfish (also known 
as crawfish and crawdads) or freshwater crabs that harbor the 
parasites. Paragonimiasis most frequently involves the lungs, 
but can affect other organs, including the brain and skin. In 
North America, Paragonimus kellicotti causes infections among 
dogs, cats, and wild carnivores, but rarely infects humans (1). 
Paragonimiasis is not a nationally notifiable condition. In 
September 2009, physicians from the Washington University 
School of Medicine (WUSM) in St. Louis published details 
of three paragonimiasis cases diagnosed since July 2006 in 
persons who had eaten raw crayfish from rivers in Missouri 
(2), prompting the Missouri Department of Health and Senior 
Services (MDHSS), CDC, and WUSM to collaborate in 
paragonimiasis surveillance and prevention. During September 
2009–September 2010, six additional cases were diagnosed in 
Missouri. These nine patients, aged 10−32 years, had fever, 
cough, pleural effusion, and eosinophilia. All had eaten raw 
or undercooked crayfish from rivers in Missouri while on 
canoeing or camping trips within 4 months of illness onset. 
Health-care providers should consider paragonimiasis when 
examining patients with unexplained fever, cough, eosinophilia, 
and pleural effusion or other chest radiographic abnormalities 
and should ask those patients whether they have eaten raw or 
undercooked crayfish.
The WUSM article (2) and reports of two paragonimia-
sis cases in October 2009 prompted MDHSS, the Missouri 
Department of Natural Resources, and the  Missouri Division 
of Tourism to distribute posters warning against eating raw 
or undercooked crayfish to campers and canoe outfitters in 
November 2009. After the sixth case was reported in April 
2010, MDHSS issued a health advisory on April 30 to enhance 
health-care provider awareness about paragonimiasis and to 
request voluntary reporting of cases. MDHSS developed an 
investigation form and revised the Missouri Health Surveillance 
Information System for reporting of paragonimiasis. In May, 
WUSM issued a press release to publicize the series of six cases, 
resulting in an additional patient (patient 7) seeking evalua-
tion in June, 10 months after illness onset and after having 
undergone multiple diagnostic tests and failed treatments. In 
September, a medical center in northwest Missouri reported 
the other two cases.
Clinical information and exposure histories were collected 
through medical record review and interviews of patients and 
the parents of a patient by attending physicians. Sputum, stool, 
pleural effusion, and lung biopsies, if available, were examined 
microscopically for Paragonimus parasites or eggs. Serum samples 
were tested for Paragonimus antibodies by enzyme-linked immu-
nosorbent assay (ELISA) at a commercial laboratory or by immu-
noblot assay at CDC. Seven patients lived in Missouri and two in 
Illinois (Table). All nine patients had eaten raw or undercooked 
crayfish directly taken from rivers in Missouri (i.e., Current, Jacks 
Fork, Huzzah, Little Niangua, and Meramec) while canoeing or 
camping within the months of May–August during 2006–2010. 
Among the eight adults, seven had eaten raw crayfish during group 
canoe trips, and the other had eaten undercooked crayfish while 
camping. Seven adults had eaten raw or undercooked crayfish after 
alcohol consumption; two had eaten raw crayfish on dares. The 
child had eaten a small raw crayfish while camping to demonstrate 
outdoor survival skills to other children.
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Illness onset ranged from 2−16 weeks after cray-
fish ingestion. Common signs and symptoms were 
fever (100%), cough (100%), weight loss (56%), 
malaise (56%), chest pain (44%), dyspnea (44%), 
myalgia (44%), and night sweats (44%). Cough was 
not among the earliest indicators for patients 1, 4, 
and 7. Patient 1 experienced fever and headache 3 
weeks before the onset of mild nonproductive cough. 
Two patients (patients 4 and 7) experienced upper-
abdominal pain 6−8 weeks after crayfish ingestion. 
Patient 4 underwent emergency cholecystectomy for 
suspected acute cholecystitis, but his resected gall 
bladder was normal. Patient 7 experienced acute chest 
pain 2 weeks after experiencing abdominal pain. In 
addition, patient 8 experienced bilateral spontane-
ous pneumothoraces 3 weeks after the onset of fever, 
dyspnea, and nonproductive cough. These clinical 
manifestations likely were caused by P. kellicotti 
migration through the diaphragm into the pleural 
space and lungs.
During routine clinical care, all patients received 
a presumptive diagnosis of paragonimiasis 3−45 
weeks after illness onset. All had eosinophilia (range: 
850−3,900 eosinophils/mm3; eosinophil percentage: 










(wks) Basis of diagnosisDate Source river
1 31 Male Jun 2006 Jacks Fork 
and Current
2 3 Clinical history and findings, and response to therapy; IB negative
2 26 Female Jul 2007 Meramec 2 12 ELISA positive
3 32 Male Aug 2007 Current 3 12 ELISA positive
4 28 Male Jun 2009 Huzzah 8 12 ELISA positive; IB negative
5 10 Male May 2009 Current 16 3 Clinical history and findings, and response to therapy; IB negative
6 20 Male Jun 2009 Jacks Fork 12 36 IB positive
7 22 Male Aug 2009 Jacks Fork 6 40 Sputum cytology, IB positive
8 18 Male Jun 2010 Jacks Fork 3 10 IB positive
9 27 Male Aug 2009 Little Niangua 12 45 Bronchoalveolar lavage fluid cytology, IB positive
Abbreviations: ELISA = enzyme-linked immunosorbent assay; IB = immunoblot assay.
MMWR  Morbidity and Mortality Weekly Report
 MMWR  /  December 10, 2010  /  Vol. 59  /  No. 48 1575 
7%−40%) and pleural effusion. Pleural effusions were 
analyzed for six patients. Five patients had eosinophilic 
pleural effusion, defined as a pleural effusion with 
≥10% eosinophils (eosinophil percentage: 44%−90%; 
normal: ≤3%). Other chest radiologic abnormalities 
included pulmonary nodules (four patients), pericar-
dial effusion (three patients), pulmonary infiltrates 
(three patients), and pneumothorax (one patient). 
Extrapulmonary complications included migratory 
skin nodules (four patients), cardiac tamponade (one 
patient), and cerebral lesions (one patient) associated 
with blurred vision.
P. kellicotti eggs were identified in sputum or 
bronchoalveolar lavage fluid from two patients 40–45 
weeks after illness onset. Paragonimus antibodies were 
positive by ELISA or immunoblot for seven patients 
(Table). Among seven patients (patients 1 and 4−9) 
whose serum samples were tested for Paragonimus 
antibodies by immunoblot, three (patients 1, 4, and 5) 
tested negative in two consecutive serum samples col-
lected ≥1 month apart. An acute serum from patient 4 
was tested by ELISA; the result was positive. Patients 
1 and 5 were diagnosed on the basis of their clinical 
histories and findings and response to therapy.
All patients were treated with 75 mg praziquantel 
per kilogram of body weight in 3 divided doses for 
2–3 days. Their symptoms promptly improved. All 
symptoms, eosinophilia, and radiographic abnormali-
ties resolved within 1−3 months of treatment.
Reported by
SL Patrick, PhD, G Turabelidze, MD, H Marx, 
A Grim, MPH, Missouri Dept of Health and Senior 
Svcs; MA Lane, MD, GJ Weil, MD, TC Bailey, MD, 
NF Önen, MD, Infectious Disease Div; LM Demertzis, 
MD, PG Tuteur, MD, Pulmonary Div, Dept of Medi-
cine, EV Hayes MD, SZ Davila, MD, Dept of Pedi-
atrics, Washington Univ School of Medicine, St. Louis; 
SM Folk, MD, RE Mitchem, DO, E Kammerer, MD, 
Heartland Regional Medical Center, St. Joseph, Mis-
souri. LP Fannon Jr, Atlanta Research and Education 
Foundation, Georgia. JL Jones, MD, PP Wilkins, PhD, 
Div of Parasitic Diseases and Malaria, Center for Global 
Health; YC Lo, MD, EIS Officer, CDC.
Editorial Note
During 1965–2007, only six other cases of non-
imported paragonimiasis were reported in the United 
States, occurring in Colorado, Iowa, Michigan, 
Missouri, and Oklahoma. Among those six patients, 
five had eaten crayfish (3−8). This report of nine cases 
recently identified in Missouri highlights the need for 
increased awareness of this underrecognized disease 
and public education to prevent it.
The life cycle of P. kellicotti requires two intermedi-
ate hosts. The first intermediate host is a snail (e.g., 
Pomatiopsis lapidaria), and the second is crayfish, 
principally Cambarus spp. (1). After humans eat raw 
or undercooked crayfish that harbor P. kellicotti, the 
parasite penetrates through the intestinal wall into 
the peritoneal cavity, then through the diaphragm 
into the pleural space and lungs, and can migrate to 
other organs, including the brain and skin. Eggs laid 
in lungs are excreted in sputum, or swallowed and 
passed with stool. Paragonimus species are endemic in 
Africa, the Americas, and Asia, but the distribution 
of P. kellicotti is still being determined (1).
Behavioral factors that led patients in this report 
to eat raw or undercooked crayfish included alcohol 
consumption, dares, and demonstration of survival 
skills. Eight of the nine patients were males. Although 
crayfish commonly is regarded as food in survival 
situations, persons who learn or practice survival skills 
should be cautioned that eating raw or undercooked 
crayfish carries a risk for paragonimiasis and other 
diseases (9). Owners and customers of campgrounds 
and canoe rental businesses should be alerted to 
thoroughly cook crayfish before eating. The Food and 
What is already known on this topic?
Paragonimiasis, a rare parasitic disease in the United 
States, is caused by Paragonimus trematodes (lung 
flukes) that infect humans who eat raw or under-
cooked crayfish or freshwater crabs that harbor the 
parasites.
What is added by this report?
During July 2006–September 2010, nine cases of 
paragonimiasis were identified by physicians within 
4 months of illness onset in patients who had eaten 
raw or undercooked crayfish from rivers in Missouri 
while canoeing or camping.
What are the implications for public health practice?
Efforts are needed to educate the public, especially 
persons involved in recreation along streams and 
rivers, to avoid eating uncooked crayfish. Health-
care providers should consider paragonimiasis in 
patients who have eaten raw or undercooked crayfish 
and have unexplained fever, cough, eosinophilia, 
and pleural effusion or other chest radiographic 
abnormalities.
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Drug Administration advises cooking shellfish to an 
internal temperature of 145°F (63°C).*
Early symptoms of paragonimiasis include diar-
rhea, abdominal pain, and fever, which can occur 
2−15 days after eating infected crayfish. Later mani-
festations include fever, cough, hemoptysis, and chest 
radiographic abnormalities, which occur when the 
parasite migrates to lungs. Migration of the parasite 
to the brain can cause severe complications, including 
vision loss. Eosinophilia in blood or pleural effusion 
is a supportive laboratory finding.
Definitive paragonimiasis diagnosis classically is 
based on viewing Paragonimus eggs or parasites in 
tissues or bodily fluids by microscope, although the 
eggs typically are not present until 2−3 months after 
infection. P. kellicotti eggs were evident in sputum, 
bronchoalveolar lavage fluid, pleural effusion or 
biopsies, or lung biopsies in previous reports and in 
two cases described in this report; the intervals from 
illness onset to parasitologic diagnosis ranged from 1 
month to 5 years (4−9). Serologic testing is an impor-
tant tool for diagnosing infections with Paragonimus 
westermani, a related fluke, but experience with its use 
in P. kellicotti infection is limited. ELISA is easier to 
perform, but might not provide positive results until 
the P. kellicotti infection has progressed 4−24 months 
(1). CDC’s immunoblot assay targets antibodies 
directed against P. westermani antigens and is highly 
sensitive (96%) and specific (99%) for P. westermani 
infection (10). Although existing serologic methods 
using P. westermani antigens might be less sensitive for 
early detection of P. kellicotti infection, a positive result 
is useful in confirming the diagnosis. Immunoblot 
assay was positive as early as 10 weeks after illness 
onset in one case described in this report.
Health-care providers should consider parago-
nimiasis and inquire about ingestion of raw or under-
cooked crayfish among patients with unexplained 
fever, cough, eosinophilia, and pleural effusion or 
other chest radiographic abnormalities. Empiric treat-
ment with praziquantel is warranted for patients with 
signs and symptoms consistent with paragonimiasis 
and a history of eating raw or undercooked crayfish, 
regardless of serology results, particularly with an ill-
ness of <3 months duration.†
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Enteroviruses, members of the Picornaviridae 
family, are common viruses associated with clinical 
manifestations ranging from mild respiratory symp-
toms to serious conditions, including aseptic menin-
gitis, encephalitis, neonatal sepsis, and acute flaccid 
paralysis. Approximately 100 serotypes of nonpolio 
enteroviruses have been recognized (1), and some 
viruses previously classified as enteroviruses, namely 
echovirus 22 and 23, recently have been reclassified 
as human parechoviruses (HPeVs), a different genus 
within the Picornaviridae family. This report describes 
trends in nonpolio enterovirus and HPeV detec-
tions during 2006–2008, based on data from two 
laboratory-based surveillance systems, the National 
Enterovirus Surveillance System (NESS) and, for the 
first time, the National Respiratory and Enteric Virus 
Surveillance System (NREVSS). As in previous years, 
approximately 70% of detections occurred during 
July–October, the peak enterovirus season. The five 
most common enterovirus serotypes (coxsackievirus 
B1 [CVB1], echovirus 6, echovirus 9, echovirus 18, 
and coxsackievirus A9) accounted for 54% of total 
serotyped detections. During 2006–2008, southern 
states reported the most serotyped enterovirus detec-
tions, followed by midwestern states, western states, 
and the northeastern states. In 2007 and 2008, CVB1 
was the predominant serotype detected, accounting 
for 24% and 19% of overall detections, respectively. 
In 2007, CVB1 was implicated in an outbreak of 
serious neonatal infections in the United States (2). 
Understanding trends in enterovirus and HPeV cir-
culation can help clinicians decide when to test for 
these infections. Also, more timely reporting of data 
could help public health officials recognize outbreaks 
associated with these viruses.
NESS, initiated in 1961, is a passive, volun-
tary surveillance system that monitors laboratory 
detections of enteroviruses in the United States. 
Participating laboratories are encouraged to report 
enterovirus detections by serotype, specimen type, 
collection date, age of patient, and sex of patient to 
CDC monthly. Enterovirus serotyping is performed 
by sequencing the genome region encoding the VP1 
capsid protein by immunofluorescence using type-
specific monoclonal antibodies, or by neutralization 
with type-specific polyclonal antisera.
NREVSS is a passive, voluntary, laboratory-based 
surveillance system that tracks temporal and geo-
graphic trends in the circulation of respiratory and 
enteric pathogens. NREVSS began collecting entero-
virus reports in July 2007. It collects the number of 
enterovirus tests and the proportion that are positive, 
by specimen site and collection date; no serotyping, 
demographic data, or clinical data are reported. All 
participating laboratories that reported at least one 
enterovirus-positive specimen were included in this 
analysis. Enteroviruses were detected by cell culture or 
nucleic acid detection (polymerase chain reaction).
During 2006–2008, enterovirus and HPeV detec-
tions were reported from 49 states through one or 
both of these surveillance systems during the years 
specified (Figure 1). A total of 20 laboratories (includ-
ing 18 public health laboratories, one private refer-
ence laboratory, and CDC’s Picornavirus Laboratory) 
reported results to NESS. Public health and private 
laboratories without the capacity to serotype send 
specimens to CDC Picornavirus Laboratory for sero-
typing. A total of 1,632 enterovirus or HPeV detec-
tions were reported to NESS during this period (920 
from public health laboratories, 661 from the one 
reference laboratory, and 51 from CDC’s Picornavirus 
Laboratory). Of these detections, 1,103 (68%) were 
reported during July–October. The age of patients for 
whom age was known (1,415 [87%]) ranged from 
<1 month to 79 years, with a mean age of 9 years 
and a median age of 2 years. Children aged ≤1 year 
accounted for 660 (47%) of these 1,415 enterovirus 
or HPeV detections for which the age of patient was 
known. Cerebral spinal fluid was the most common 
source for detections, accounting for 743 (51%) of 
the 1,468 reports of known specimen type, followed 
by 324 (22%) detections from throat-nasopharyngeal 
specimens, 268 (17%) from stool-rectal swabs, and 
133 (10%) from tissue specimens.
Enterovirus or HPeV serotypes were specified for 
1,171 (72%) NESS reports. By region,* southern 
states had the most serotyped detections reported, 
Nonpolio Enterovirus and Human Parechovirus Surveillance — 
United States, 2006–2008
* Midwest: Illinois, Indiana, Kansas, Michigan, Minnesota, Missouri, 
Ohio, and Wisconsin; Northeast: Massachusetts, New Jersey, and 
New York; South: Florida, Georgia, Kentucky, Louisiana, Maryland, 
North Carolina, Oklahoma, and Tennessee; West: Alaska, Arizona, 
California, Colorado, Hawaii, Nevada, New Mexico, Oregon, Utah, 
and Washington.
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accounting for 418 of 1,167 (36%) reports for 
which state information was provided, followed 
by 373 (32%) detections from midwestern states, 
222 (19%) from western states, and 154 (13%) 
from northeastern states. The five most common 
enterovirus serotypes accounted for 54% of total 
detections with a known serotype in 2006–2008 
(Table). Overall, during 2006–2008, CVB1 was the 
most commonly detected enterovirus identified in 
235 (17%) of 1,171 specimens tested (Table). In 
2007, CVB1 was detected in 22 mostly southern 
and western states; two states reported 70 (51%) of 
137 detections. In 2008, CVB1 was detected in 10 
states; one state reported 15 (34%) of 44 detections. 
During 2006–2008, three public health laboratories 
and CDC’s Picornavirus Laboratory reported a total 
of 21 HPeV type 1 (HPeV1) detections. HPeV1 was 
one of the 15 most common enteroviruses reported 
during the surveillance period but was detected in 
<2% of specimens (Table). During the surveillance 
period, only 14 cases of enterovirus 71 (EV71), a virus 
that has caused widespread outbreaks of hand, foot, 
and mouth disease in several Asian countries (3), were 
reported to NESS, and it was not included as one of 
the 15 most common serotypes reported.
During July 2007–December 2008, a total of 3,192 
(3%) of the 108,798 reports sent to NREVSS were 
positive for enterovirus. One hundred laboratories 
reported testing for enteroviruses to NREVSS. During 
this period, the highest proportion of detections was 
reported during July–October (Figure 2). The pro-
portion of enterovirus-positive specimens was similar 
across regions.
Reported by
GR Villarruel, MPH, GE Langley, MD, MS Oberste, 
PhD, M Pallansch, PhD, Div of Viral Diseases, National 
Center for Immunizations and Respiratory Diseases, 
CDC.
Editorial Note
The findings in this report are consistent with pre-
vious trends regarding the most commonly detected 
enterovirus serotypes (4). During 2006–2008, CVB1 
became the predominant enterovirus serotype identi-
fied, found in several states, and concentrated in a 
few. Common clinical presentations of CVB1 include 
aseptic meningitis, myocarditis, pleurodynia, and 
hand, foot, and mouth disease. CVB1 generally shows 
an epidemic pattern of circulation with irregular 
intervals of increased circulation usually lasting 2–3 
years (4). During 1970–2005, CVB1 accounted for 
approximately 2% of reports with known serotype, 
with an increase of CVB1 observed in the early 
1990s and then again in the early 2000s (4). In 2007, 
increased detections of CVB1 reported to NESS led 
to an investigation that identified severe neonatal 
disease and deaths associated with CVB1 infection 
in multiple states (2,5).
Since 1997, EV71 has caused widespread out-
breaks of hand, foot, and mouth disease in several 
Asian countries (3). A small proportion of cases have 
resulted in encephalitis and death. In the United 
States, small clusters of serious disease were detected 
during 2003–2005 (6). Although there was an 
increase in reported EV71 detections in the United 
States during 2006–2008, EV71 detections were 
uncommon. 
HPeV1 usually has been associated with mild 
gastrointestinal and respiratory symptoms, menin-
gitis, and neonatal sepsis (7). HPeV1 was one of the 
15 most common detections during 2006–2008; no 
other HPeV types were reported during that period. 
HPeV cannot be detected by EV-specific assays. 
CDC’s Picornavirus Laboratory has performed the 
majority of HPeV typing reported to NESS but has 
worked with clinical and state laboratories to enhance 
their HPeV diagnostic and molecular typing assays 
FIGURE 1. Method of reporting enterovirus detections, by state — National 
Enterovirus Surveillance System (NESS) and National Respiratory and Enteric 
Virus Surveillance System (NREVSS), United States, 2006–2008
Reporting to NREVSS
Reporting to NESS
Reporting to NREVSS and NESS
No reporting
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(8) to improve detections and enhance parechovirus 
surveillance.
The findings in this report are subject to at least 
four limitations. First, enteroviral infections other 
than poliovirus infections are not nationally notifiable 
in the United States. NESS is a passive system that 
relies on voluntary participation from laboratories, so 
findings are not necessarily representative of national 
or regional enterovirus activity. Although there might 
be more reports emanating from one state or region, it 
might not represent an increased burden of disease in 
that state or region. Second, the findings are limited 
by the lack of clinical information; however, most 
FIGURE 2. Percentage of specimens testing positive for enterovirus, by month of report — National Respiratory and 






















TABLE. Distribution of the 15 most commonly reported nonpolio enterovirus and parechovirus serotypes, by rank and year — National 
Enterovirus Surveillance System, United States, 2006–2008
Rank
2006 (n = 353) 2007 (n = 582) 2008 (n = 236) 2006–2008 (N = 1,171)
Serotype % Serotype % Serotype % Serotype %
1 Echovirus 6 15.3 Coxsackievirus B1 23.6 Coxsackievirus B1 18.6 Coxsackievirus B1 16.5
2 Echovirus 9 13.0 Echovirus 18 12.9 Echovirus 30 17.0 Echovirus 6 10.7
3 Coxsackievirus A9 11.9 Echovirus 9 10.5 Echovirus 6 11.9 Echovirus 9 10.7
4 Coxsackievirus B5 9.6 Coxsackievirus B4 10.0 Echovirus 9 7.6 Echovirus 18 8.8
5 Coxsackievirus B3 9.1 Echovirus 11 8.4 Echovirus 11 6.4 Coxsackievirus A9 7.5
6 Coxsackievirus B2 7.1 Echovirus 6 7.4 Coxsackievirus A9 5.9 Coxsackievirus B4 6.7
7 Coxsackievirus B4 4.5 Coxsackievirus A9 5.5 Echovirus 18 5.1 Echovirus 11 5.8
8 Echovirus 18 4.5 Coxsackievirus B3 3.9 Coxsackievirus A16 4.2 Coxsackievirus B3 5.4
9 Coxsackievirus B1 3.7 Coxsackievirus B5 2.4 Coxsackievirus B3 3.4 Echovirus 30 4.5
10 Echovirus 7 3.4 Echovirus 25 1.9 Human parechovirus 1 2.1 Coxsackievirus B5 4.4
11 Echovirus 30 2.8 Coxsackievirus B2 1.9 Echovirus 31 2.1 Coxsackievirus B2 3.4
12 Human parechovirus 1 1.9 Human parechovirus 1 1.6 Enterovirus 71 2.1 Echovirus 25 1.8
13 Enterovirus 71 1.9 Echovirus 7 1.2 Coxsackievirus B2 1.7 Human parechovirus 1 1.8
14 Echovirus 25 1.7 Echovirus 5 1.0 Coxsackievirus B4 1.7 Echovirus 7 1.7
15 Coxsackievirus A10 1.4 Echovirus 30 0.9 Echovirus 25 1.7 Coxsackievirus A16 1.7
Total 91.8 93.1 91.5 91.5
detections likely represent serious disease because 
cerebral spinal fluid was the most common source of 
detection. Third, most testing is performed during the 
summer months; circulation during other parts of the 
year might go undetected. Finally, although monthly 
NESS reporting is encouraged, not all participating 
laboratories submit timely data, which can delay 
accurate reporting.
NESS could be improved with more regular 
reporting by current laboratories and by increasing 
the number of participating laboratories. NREVSS 
provides enterovirus activity over a wider geographic 
area because more laboratories participate in the 
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system, but it does not provide serotype or demo-
graphic information. The combined systems provide 
the best available data on enterovirus circulation in 
the United States.
 Since July 2009, a simplified, Internet-based 
NESS system has allowed participating laboratories to 
easily input enterovirus detection data and to analyze 
national and state-based trends in enterovirus surveil-
lance, by serotype. Additional information about this 
system is available by e-mail (ness@cdc.gov).
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What is already known on this topic?
Approximately 100 serotypes of nonpolio entero-
viruses have been recognized and are associated 
with mild to serious conditions, including aseptic 
meningitis, encephalitis, neonatal sepsis, and acute 
flaccid paralysis, especially during the summer and 
fall months.
What is added by this report?
During 2006–2008, the five most frequently detected 
enteroviruses were coxsackievirus B1 (CVB1), 
echovirus 6, echovirus 9, echovirus 18, and coxsacki-
evirus A9; these accounted for 54% of total known 
serotyped detections during that period. In 2007 
and 2008, CVB1 became the predominant serotype 
detected, accounting for 24% and 19% of overall 
detections, respectively.
What are the implications for public health practice?
Understanding trends in enterovirus and human 
parechovirus circulation can help clinicians decide 
when to test for these infections and can guide public 
health officials to recognize outbreaks associated 
with these viruses, as was the case with an outbreak 
of serious neonatal infections associated with CVB1 
in 2007.
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India is one of only four countries (including 
Afghanistan, Nigeria, and Pakistan) where wild polio-
virus (WPV) transmission has never been interrupted 
(1). Historically, WPV transmission in India has 
centered largely in Uttar Pradesh and Bihar, two states 
with low routine vaccination coverage, large migrant 
and remote populations, and lower relative vaccine 
effectiveness than other areas of the country (2–4). 
However, during a 9-month period from November 
2009 to August 2010, no WPV type 1 (WPV1) 
cases were reported in Uttar Pradesh or Bihar. This 
report summarizes the substantial progress made 
in India toward polio eradication during January 
2009–October 2010, according to data reported as 
of December 4, and updates previous reports (2,4). 
During January–October 2010, only 40 WPV cases 
were confirmed in India, a 94% decrease from the 
626 WPV cases confirmed during the same period 
in 2009; the decrease likely resulted, in large part, 
from the introduction of bivalent oral poliovirus vac-
cine types 1 and 3 (bOPV). Increasingly important 
contributors to WPV transmission are large migrant 
subpopulations; surveys have indicated that up to 
11% of children aged <5 years in these subpopulations 
were missed during supplementary immunization 
activities (SIAs). Interruption of all WPV transmission 
in India will require maintaining high levels of immu-
nity in Uttar Pradesh and Bihar and additional efforts 
directed toward children in migrant subpopulations 
that are not vaccinated as readily during SIAs.
Immunization Activities
Using population-based survey data, India estimated 
nationwide routine coverage with 3 doses of oral poliovi-
rus vaccine (OPV) at 66% among children aged 12–23 
months during 2007–2008, the most recent years for 
which coverage data were available (5). Routine coverage 
estimates in Bihar (53%) and Uttar Pradesh (40%) were 
among the lowest in the country (5).
SIAs* conducted in India during 2009–2010 
(Figures 1 and 2) included two national immunization 
days (NIDs) each year. In addition, seven subnational 
immunization days (SNIDs) and four large-scale 
(multidistrict) mop-up† activities were conducted dur-
ing 2009, and five SNIDs and three large-scale mop-
ups were conducted during January–October 2010 
(Figure 1). After introduction of bOPV in January 
2010, six SIAs were conducted using bOPV.
In 2010, SIA monitoring data§ indicated >99% 
coverage among children aged <2 years in Bihar and 
>97% in Uttar Pradesh. After enhanced efforts during 
2009–2010 to identify specific areas in other states 
where migrant populations resided, directed surveys 
conducted with specific migrant subpopulations 
(e.g., construction laborers, nomads, and brick kiln 
workers) after SIA rounds indicated that 3%–11% 
of children aged <5 years had been missed. In Uttar 
Pradesh during 2010, surveys after SIAs indicated 
that, on average, 4.1% of children in the migrant 
subpopulations, compared with 2.2% missed among 
children aged <5 years in the general population.
WPV Surveillance
Acute flaccid paralysis (AFP) surveillance. The 
national nonpolio AFP rate,¶ a measure of surveillance 
system sensitivity, was 11.4 per 100,000 children aged 
<15 years in 2009 and 11.1 per 100,000 (annualized) 
during January–October 2010. The highest state-level 
nonpolio AFP rates were in Bihar (33.9) and Uttar 
Pradesh (22.8) in 2010. Adequate stool specimen col-
lection** in India was 83% in 2009 and 84% during 
January–October 2010.
Environmental surveillance. Wastewater testing 
for poliovirus began in Mumbai in January 2001 and 
in Delhi in May 2010. Although WPV was isolated 
frequently from samples taken in Mumbai in previous 
years, no WPV was detected in Mumbai wastewater 
Progress Toward Poliomyelitis Eradication — India, January 
2009–October 2010
* SIAs are mass campaigns conducted over a period of multiple days 
in which 1 dose of OPV is administered to all children aged <5 
years, regardless of vaccination history. Surveillance data analysis 
determines the geographic extent of campaigns (i.e., national or 
subnational).
 † Mop-up rounds are intensive house-to-house SIAs conducted 
in a limited area (groups of districts) with evidence of recent 
transmission.
 § SIA monitoring data are obtained from systematic surveys 
conducted after every SIA in high-risk areas to identify children 
aged <5 years who were missed with vaccination.
 ¶ The nonpolio AFP rate is the number of AFP cases not caused by 
WPV per 100,000 children aged <15 years. India’s operational 
target for each district is two or more AFP cases per 100,000.
 ** The percentage of reported AFP cases with two stool specimens 
collected within 14 days of paralysis onset (target: ≥80%).
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in 2010. Environmental testing during May–August 
2010 detected both WPV1 and WPV type 3 (WPV3) 
in wastewater at Delhi sites. Genetic analysis has 
suggested WPV circulation within Delhi was linked 
to 2009 WPV1 and WPV3 Bihar isolates. No WPV 
has been detected in environmental samples since 
mid-August.
Laboratory network. During January–October 
2010, >90% of stool specimens submitted for virus 
isolation had laboratory results reported within 14 
days of specimen receipt. The mean interval from 
onset of paralysis and confirmation of WPV isolation 
was 24 days.††
WPV Epidemiology
During all of 2009, a total of 741 WPV cases were 
reported in India from 56 districts in nine states of 
35 states/union territories in India (Figure 3). During 
January–October 2010, a total of 40 WPV cases had 
been reported from 17 districts in seven states, a 94% 
decrease from the 626 WPV cases from 52 districts 
in nine states during the same reporting period in 
2009. Among the 40 WPV cases reported in 2010, 28 
(70%) occurred in children aged <2 years. Six (15%) 
of the 40 children had received 1–3 OPV doses, eight 
(20%) had received 4–7 doses, and 25 (63%) had 
received >7 doses; one child had unknown vaccination 
status. In Uttar Pradesh and Bihar, 19 cases had been 
reported from 10 districts; all of these patients had 
received >7 OPV doses. According to data reported 
as of December 4, 2010, during January–October 
2010, a total of 17 WPV1 and 23 WPV3 cases were 
confirmed, representing a 78% decrease from 76 
WPV1 cases and a 96% decrease from 550 WPV3 
cases confirmed during the same period in 2009.
 †† The eight polio laboratories in India processed 100,102 stool 
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FIGURE 1. Number of wild poliovirus (WPV) cases, by type, month of onset, and type of supplementary immunization activity — India, 
January 2005–October 2010
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WPV1. In 2009, a total of 80 WPV1 cases were 
reported (including one case with both WPV1 and 
WPV3 isolated) from 35 districts in six states. During 
January–October 2010, a total of 17 WPV1 cases were 
reported from seven districts in five states. WPV1 
isolates related to 2009 Bihar WPV1 strains have been 
isolated from AFP patients with onset of paralysis 
during January–October 2010 in West Bengal (five 
patients), Jharkhand (three), and Maharashtra (five). 
In addition, WPV1 strains circulating in Bihar during 
2009 were associated with a WPV1 case in Jammu 
and Kashmir in 2010 after importation into Punjab 
in 2009. The most recent WPV1 case in India had 
onset on September 21 in West Bengal.
The last confirmed WPV1 case in Uttar Pradesh 
was in a patient with onset of paralysis on November 
13, 2009. In Bihar, no WPV1 cases were reported from 
October 30, 2009, to August 7, 2010. Subsequently, 
three cases have been reported in a single Bihar district 
bordering Nepal (Champaran East), with onset in the 
most recent case on September 1. The recent Bihar 
outbreak began after an outbreak was identified in 
Nepal in May 2010 immediately across the border 
from Champaran East; WPV1 isolates from both 
areas are related to WPV1 strains circulating in Bihar 
during 2009.
WPV3. In 2009, a total of 661 WPV3 cases were 
reported from 47 districts in eight states; 569 (86%) 
were from Uttar Pradesh, and 79 (12%) were from Bihar. 
During January–October 2010, a total of 23 cases were 
reported from 12 districts in five states, compared with 
550 cases from 43 districts in seven states during the 
same 10-month period in 2009. Of the 23 cases reported 
during January–October 2010, 10 (43%) were from 
Uttar Pradesh, six (26%) from Bihar, four (17%) from 
Jharkhand, two (9%) from West Bengal, and one (4%) 
from Haryana. The most recent WPV3 case in India had 
























FIGURE 2. Number of supplementary immunization activity (SIA)* rounds, by vaccine used  and district — Uttar Pradesh, Bihar, and surrounding 
areas, India, January 2009–October 2010
Abbreviations:  mOPV1 = monovalent oral poliovirus vaccine type 1; mOPV3 = monovalent oral poliovirus vaccine type 3; tOPV = trivalent oral poliovirus vaccine; 
bOPV = bivalent oral poliovirus vaccine.
* SIAs are mass campaigns conducted over a period of multiple days in which 1 dose of oral polio vaccine is administered to all children aged <5 years, regardless of 
vaccination history. Surveillance data analysis determines the geographic extent of campaigns (i.e., national or subnational).
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Editorial Note
During 2009–2010, India made substantial 
progress toward polio eradication. The absence of 
reported WPV1 cases in Uttar Pradesh and Bihar for 
9 months during November 2009–August 2010 was 
unprecedented; Uttar Pradesh has remained free of 
detected WPV cases since April 2010. For the first 
10 months of 2010, the total number of WPV cases 
in India reached a new low at 40, compared with 626 
cases during the same reporting period in 2009.
The introduction of bOPV in SIAs beginning in 
January 2010 likely contributed substantially to the 
simultaneous reduction in WPV1 and WPV3 cases. 
Previous SIAs were conducted predominantly using 
monovalent oral poliovirus vaccine type 1 (mOPV1) 
and occasionally monovalent oral poliovirus vaccine 
type 3 (mOPV3); trivalent oral poliovirus vaccine 
(tOPV) was used less often because higher type-
specific seroconversion per dose has been observed 
with mOPV formulations than with tOPV (3,6). A 
recent clinical trial demonstrated the superiority of 
bOPV compared with tOPV and noninferiority com-
pared with mOPV1 and mOPV3 (7). Once supplies 
became available, bOPV became the predominant 
formulation used in SIAs. Preliminary data from 
August 2010 seroprevalence studies among infants 
aged 6–7 months in high-risk areas of Uttar Pradesh 
and Bihar indicate that, after bOPV introduction, 
seroprevalence against WPV3 increased and high 
levels of seroprevalence against WPV1 were main-
tained (Enterovirus Research Center, Mumbai, India, 
unpublished data, 2010).
* Data of December 4, 2010.










FIGURE 3. Wild poliovirus (WPV) cases, by type — India, 2009 and 2010*
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Appropriately targeted environmental surveillance 
can be more sensitive in detecting low-level WPV 
circulation than AFP surveillance (8). WPV was last 
detected in sewage in Mumbai in May 2009 and in 
Delhi in mid-August 2010, where sewage sampling 
was initiated in May of this year. The recent lack of 
detection of WPV in any samples is encouraging; 
however, sewage sampling in India still is restricted 
to these two major metropolitan areas.
Despite India’s gains in 2010, the risk remains for 
WPV circulation and reintroduction among migrant 
populations and residents of high-risk areas in western 
Uttar Pradesh and central Bihar, primarily because of 
high population density, weak routine immunization, 
and suboptimal hygiene and sanitation. Families of cer-
tain migrant subpopulations (e.g., construction laborers, 
nomads, and brick kiln workers) that move regularly 
to and from Uttar Pradesh and Bihar have higher pro-
portions of undervaccinated children than the general 
population, according to 2010 directed surveys of these 
subpopulations and supported by reported vaccination 
rates among nonpolio AFP case patients.
The risk for persistence of low-level, undetected, 
WPV transmission among Uttar Pradesh or Bihar 
residents, or among migrant subpopulations, is a 
concern. All WPV1 isolates from India and Nepal 
in 2010 are genetically linked to strains detected in 
central Bihar in 2009, and the 2010 WPV1 outbreak 
in Tajikistan was linked to WPV1 from Uttar Pradesh 
in 2009 (9). OPV-vaccinated children with serologic 
immunity can excrete WPV, which might contribute 
to transmission despite high OPV coverage in SIAs 
(6,10). Moreover, transmission has continued in some 
areas with recent outbreaks (Maharashtra and West 
Bengal). WPV could spread to other parts of India 
with relatively low population immunity months after 
the last observed case in the outbreak area.
The current high season for polio in India has passed 
with historically low incidence of WPV cases. Successful 
interruption of all residual WPV transmission in India 
will require maintaining high levels of immunity in 
Uttar Pradesh and Bihar through SIAs and programs to 
strengthen routine vaccination, along with continued 
mop-ups to control outbreaks in areas where WPV 
was reintroduced. SIAs planned for 2011 represent an 
opportunity to interrupt transmission, provided that 
high coverage during SIAs is maintained, immediate 
large-scale mop-ups are conducted in response to any 
new WPV detected, and focus is continued on vigorous 
vaccination of migrant subpopulations.
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What is already known on this topic?
India is one of four countries (including Afghanistan, 
Nigeria, and Pakistan) where wild poliovirus (WPV) 
remains endemic; most cases in India in the past have 
been reported in Uttar Pradesh and Bihar, two states with 
low routine vaccination coverage, lower vaccine effec-
tiveness than elsewhere, and large migrant subpopula-
tions that require frequent supplementary immunization 
activities (SIAs) to control WPV transmission.
What is added by this report?
As of December 4, during January–October 2010, a 
total of 40 WPV cases had been confirmed in 2010, a 
94% decrease from the 626 WPV cases during the same 
10-month period in 2009; this progress likely resulted 
in large part from the introduction of bivalent oral 
poliovirus vaccine types 1 and 3 (bOPV) in SIAs.
What are the implications for public health practice?
Despite the progress in India, the risk for persistent 
WPV transmission remains, particularly in migrant 
subpopulations and among residents of Uttar Pradesh 
and Bihar. To interrupt all WPV transmission, India is 
taking steps to strengthen routine vaccination and 
SIA coverage, implement immediate, large-scale 
mop-ups in response to new cases, target migrant 
subpopulations, and maintain high levels of immunity 
in Uttar Pradesh and Bihar.
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On December 8, 2010, this report was posted 
as an MMWR Dispatch on the MMWR website 
(http://www.cdc.gov/mmwr).
The first cholera outbreak in Haiti in at least 
a century was confirmed by the Haitian National 
Public Health Laboratory on October 21, 2010 (1). 
Surveillance data through December 3, provided by 
the Haitian Ministry of Public Health and Population 
(MSPP), indicated that the outbreak had spread 
nationwide and that cases of cholera and cholera-
associated hospitalizations and deaths had climbed 
rapidly in November. As of December 3, MSPP 
reported 91,770 cases of cholera from all 10 depart-
ments and the capital city of Port-au-Prince; 43,243 
(47.1%) patients had been hospitalized, and 2,071 
(2.3%) had died. A rapid mortality assessment in 
Artibonite Department found that deaths occurred as 
rapidly as 2 hours after symptom onset and identified 
important gaps in access to life-saving treatments, 
including oral rehydration solution (ORS). Urgent 
activities are under way, and additional efforts are 
imperative to reduce cholera mortality by expanding 
access to cholera treatment and to reduce cholera 
transmission by improving access to safe water and 
adequate sanitation.
A nationwide cholera surveillance system has been 
established in Haiti. Hospitals and clinics send daily 
case counts to local MSPP officials; aggregate data are 
sent on to department-level officials and then to central 
government officials. A case of cholera is defined as 
profuse, acute, watery diarrhea in a resident of a depart-
ment in which at least one case of cholera has been 
laboratory-confirmed by isolation of Vibrio cholerae 
from culture of a stool specimen. A hospitalized case 
occurs in a patient admitted to a health facility (i.e., 
a hospital or cholera treatment site) for at least one 
night. A cholera death is the death of a person with 
illness that meets the case definition for cholera. Any 
cholera death that occurs in a health facility, regardless 
of whether the decedent was admitted overnight, is 
considered a cholera hospital death. MSPP posts daily 
and cumulative tallies of cholera reports on a public 
website; tallies are stratified by department and age 
group (aged <5 years and all ages).* Since November 
16, nonhospitalized cases have been posted in addition 
to hospitalized cases.
All 10 departments and the capital city of Port-
au-Prince have reported laboratory-confirmed cases 
of cholera. As of December 3, a total of 91,770 cases 
had been reported nationwide, and 43,243 (47.1%) 
patients had been hospitalized (Figure 1). The larg-
est number of cases (42,596 [46.4%]) were reported 
from Artibonite Department, which comprises 
approximately 16% of the Haiti population (2) and 
is the department where cases were first laboratory-
confirmed (Figure 2). As of December 3, of 2,071 
deaths, 1,437 (69.4%) had occurred in hospitals. A 
total of 82,599 (90.0%) cases, 39,435 (91.2%) hos-
pitalizations, and 1,908 (92.1%) deaths had occurred 
among persons aged ≥5 years.
Nationwide, during November 27–December 3, 
the median daily number of deaths was 41 (range: 
18–64). As of December 3, the overall case-fatality 
ratio (CFR) (cumulative deaths divided by cumula-
tive cases) was 2.3%. The hospital CFR (cumulative 
hospital deaths divided by cumulative hospitalized 
cases) was 3.3%. The daily nationwide hospital 
CFR has varied; however, simple linear regression 
indicates decreases in the rolling 7-day hospital CFR 
in Artibonite (p<0.001) and in all other depart-
ments combined (p<0.001) (Figure 3). In Artibonite 
Department, the rolling 7-day hospital CFR decreased 
from a high of 4.2% on November 9 to a low of 1.4% 
on December 1 (Figure 3). 
A rapid assessment of mortality from cholera 
among persons aged ≥5 years was conducted in 
Artibonite Department during November 12–16. 
Teams visited homes of 22 cholera decedents identi-
fied through records in two hospitals. Family members 
were interviewed about decedents’ use of ORS and 
other health-care services. Family and community 
members were asked about other cholera deaths in the 
community, resulting in identification of an additional 
65 decedents, whose families also were interviewed. 
Among the total of 87 cholera decedents identified, 
58 (67%) were male; eight (9.2%) were aged 5–18 
years, and 79 (90.8%) were aged 19–100 years. Of the 
87 deaths, 48 (55%) occurred in a hospital or other 
health facility, and 39 (45%) occurred in the commu-
nity. For those who died in the community, median 
time to death from onset of symptoms was 12 hours 
* Available at http://mspp.gouv.ht/site/index.php?option=com_
content&view= article&id=57&itemid=1.
Update: Outbreak of Cholera — Haiti, 2010
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(range: 2 hours–8 days). Only nine (23%) of the 39 
persons who died in the community received ORS. 
Sixteen (41%) of the 39 had sought health care; eight 
died en route to a health facility, and eight died after 
discharge. When asked to cite reasons for not seeking 
health care, family members in 10 cases did not think 
the ill person had cholera; family members in seven 
cases reported difficulty getting to a health facility 
(including transport at night), and family members 
in six cases did not see the need to seek care.
Reported by
Ministry of Public Health and Population, Haiti. Pan 
American Health Organization. CDC.
Editorial Note
Surveillance data show that from October 21 to 
December 3, cholera spread rapidly across Haiti. 
Although decreasing, the hospital CFR of 3.3% 
remains high. Improvements in receipt of appropri-
ate care in health facilities might be reflected in the 
decreasing hospital CFR. However, when cholera 
is recognized early and appropriate rehydration 
treatment is initiated rapidly, a CFR <1% can be 
achieved among patients who have sought care (3). 
The outbreak strain of cholera has been identified as 
a “hybrid” strain of the El Tor biotype and the clas-
sic toxin type; the classic toxin might be associated 
with more severe illness, and the El Tor biotype is 
associated with longer persistence in the environ-
ment (4,5).† Underlying poor nutritional status and 
other comorbidities also are likely to contribute to 
disease severity in Haiti (6,7). In 2008, only 63% of 
Haiti’s population had access to an improved drinking 
water source,§ and only 17% had access to adequate 
sanitation (8). The lack of safe water and sanitation 
† Most toxigenic cholera strains circulating in the world today are 
biotype El Tor with some variant of the classic toxin. 
§ Defined as 1) a piped household water connection located inside 
the user’s dwelling, plot, or yard; 2) public taps or standpipes; 3) 
tube wells or boreholes; 4) protected dug wells; 5)protected springs; 
or 6) rainwater collection.
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* Because of time delays in reporting, case counts for the most recently reported days likely are underestimated.
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infrastructure in Haiti and the devastation caused 
by the January 2010 earthquake have created condi-
tions favorable for the rapid spread of cholera across 
the country. 
A cholera epidemic in the Western Hemisphere 
began in 1991 and lasted for nearly a decade, spread-
ing across Central and South America in countries 
that, like Haiti, were previously unexposed to 
cholera and thus lacked population immunity (9). 
Peru experienced the highest cholera incidence and 
mortality among affected countries. During the first 
6 full epidemiologic weeks of the cholera epidemic 
in Peru, 19,431 hospitalizations (87.5 per 100,000 
population) and 368 cholera deaths (1.7 per 100,000) 
were reported (10). By comparison, during the first 6 
full weeks of the Haiti outbreak, 39,010 hospitaliza-
tions (393 per 100,000 population) and 1,882 chol-
era deaths (19.0 per 100,000) were reported. Thus, 
early rates of reported hospitalizations and deaths in 
Haiti were substantially higher than those in Peru 
(rate ratios: 4.5 and 11.5, respectively). In fact, the 
death rate during 6 weeks of the outbreak in Haiti 
(19.0 per 100,000) exceeded the death rate observed 
during the first 48 weeks of the Peru epidemic (13.1 
per 100,000).¶ 
Urgent measures are being taken to expand access 
to treatment that will mitigate cholera morbidity and 
mortality; improvements in water quality and sanita-
tion also are necessary to reduce transmission. Because 
cholera can progress quickly to severe dehydration, 
shock, and death, rapid rehydration is the mainstay 
of cholera treatment. In the mortality assessment pre-
sented in this report, only nine of 39 cholera decedents 
who died outside of health facilities had received ORS, 
and eight died en route to care. Early access to ORS in 
homes, in communities (e.g., at specially designated 
ORS sites), and at health facilities can slow disease 
progression, reduce the need for hospitalization, and 
reduce mortality. Because cholera can lead to death 
rapidly, ideally all persons at risk for cholera should 
be within 1 hour of a location where they can receive 
ORS and should have access to more advanced care at 
specially designated cholera treatment centers. 
MSPP, the U.S. government, and multiple other 
governmental and nongovernmental entities have 
worked rapidly under challenging circumstances to 
* Artibonite 42,596; Port-au-Prince 12,566; Nord 10,436; Nord’ Ouest 9,735; Centre 9,527; Ouest 
4,899; Sud 419; Nord’ Est 341; Grande Anse 205; Sud’ Est 76; Nippes 34.
† Includes the following communes: Carrefour, Cite Soleil, Delmas, Kenscoff, Petion Ville, Port-
au-Prince, and Tabarre.
FIGURE 2. Cumulative number of cases of cholera reported overall* and date 
of first laboratory-confirmed case, by department and in Port-au-Prince†— 

























What is already known on this topic? 
Cholera is marked by profuse, acute, watery diarrhea 
that can lead to rapid dehydration and death; case-
fatality ratios can be reduced to <1% with early 
recognition and appropriate rehydration. For at least a 
century, no cholera outbreak had occurred in Haiti. 
What is added by this report? 
As of December 3, a total of 91,770 cases of cholera 
had been reported in Haiti from all 10 departments 
and the city of Port-au-Prince, including 43,243 
hospitalizations and 2,071 deaths; the case-fatality 
ratio was 2.3% overall and 3.3% among persons 
hospitalized. A mortality assessment of 87 decedents 
indicated that some deaths occurred within 2 hours 
after symptom onset and important gaps exist in 
access to life-saving rehydration.
What are the implications for public health practice?
The potential exists to prevent many cholera deaths 
in Haiti; to do so, urgent efforts are needed to rec-
ognize affected patients early, provide ready access 
to oral rehydration solution, and provide access to 
more advanced care at cholera treatment centers 
as needed. Short-term and long-term measures 
to improve water and sanitation in Haiti also are 
necessary. 
¶ Cholera death total for Peru in 1991 derived from data available 
at http://www.paho.org/english/sha/epibul_95-98/be971cho.htm. 
Peru population estimate for death rate calculations available at 
http://ais.paho.org/phip/viz/basicindicatorbrowaser.asp.
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establish, staff, and supply cholera treatment sites. To 
expand treatment options further, the United States 
is developing cholera treatment sites within health 
facilities supported by the President’s Emergency 
Plan for AIDS Relief (PEPFAR). In addition, CDC, 
MSPP, and the International Centre for Diarrhoeal 
Disease Research, Bangladesh, have developed a 
train-the-trainer program** in which health workers 
educated in cholera treatment and clinical manage-
ment techniques are providing clinical training to 
health workers across the country. Ensuring sufficient 
supplies and staffing for cholera treatment sites dur-
ing the evolving cholera outbreak will be challenging, 
and ensuring appropriate care will require systematic 
assessments of cholera treatment sites.
Short-term and long-term efforts also are needed 
to prevent cholera transmission. In the short-term, 
products for household water chlorination and safe 
water storage must be made available to all households 
and health facilities, including in communities not 
yet affected by cholera. Hand washing with soap and 
safe sanitation behaviors, including latrine use, need 
to be reinforced, and soap should be made more 
widely available. Safe food-handling practices, in 
homes and in open markets, ought to be encouraged. 
Although much work has been done by MSPP and its 
partners to improve access to safe drinking water and 
adequate sanitation in the areas of Haiti hardest hit 
by the January 2010 earthquake, additional activities 
are needed to ensure long-term access. In the coming 
months, certain efforts will be critical for reducing 
cholera transmission and mortality: 1) sustaining and 
improving drinking water chlorination; 2) improving 
access to safe drinking water sources; 3) enhancing 
water, sanitation, and hygiene education activities; 
and 4) ensuring appropriate sanitation measures in 



























FIGURE 3. Rolling 7-day hospital case-fatality ratio* for Artibonite and all other departments — Haiti, October 31– 
December 3, 2010
* Case-fatality ratio calculated as new hospital deaths divided by new hospitalizations during the 7-day period ending on that date.
 ** Information available at http://www.cdc.gov/haiticholera/training/
hcp_materials.htm.
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The findings in this report are subject to at least 
four limitations. First, cholera cases and deaths, par-
ticularly those not evaluated or occurring in health 
facilities, likely are underreported, and how reporting 
might differ among facilities and age groups is not well 
understood. Second, the mortality assessment was 
conducted in one area of Artibonite Department, and 
sampling was not systematic; as such, demographic 
characteristics, circumstances of illness, and location 
of death might not be representative of all deaths 
in the country. Third, family member responses in 
the mortality assessment might not have provided 
an accurate account of the decedent’s perceptions 
or experiences. Finally, population estimates used to 
calculate rates for cholera morbidity and mortality 
are uncertain, particularly because of the mortality 
caused by the earthquake in Haiti. 
Despite strong responses from MSPP and govern-
ments and nongovernmental agencies, the size and 
speed of this cholera outbreak, combined with the 
lack of safe water and sanitation infrastructure in 
Haiti, indicate that further action is urgently needed 
to reduce cholera transmission and mortality. All 
parties should extend their periods of involvement 
and redouble their efforts to support efforts in Haiti 
to reduce the burden of this disease.
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Notice to Readers
Update: Vol. 47, No. 9
In the report, “Human Exposure to Brucella abortus 
Strain RB51 — Kansas, 1997,” the sixth paragraph of 
the Editorial Note (page 174) mentioned efforts by 
CDC’s Special Bacteriology Reference Laboratory to 
develop a polymerase chain reaction assay for detec-
tion of human RB51 infection. However, currently 
no validated routine test is available to monitor infec-
tions associated with exposure to the RB51 vaccine 
strain. Exposure to RB51 does not elicit a measurable 
antibody response; therefore, serology cannot provide 
an indicator of infection. Persons seeking assistance 
in identifying Brucella spp. or serologic monitoring 
of exposed persons should contact their state health 
departments or the CDC Bacterial Special Pathogens 
Branch at telephone 404-639-1711. 
Postexposure prophylaxis is recommended for 
persons at high risk. A high-risk exposure is defined 
as 1) having direct personal exposure to Brucella (e.g., 
sniffing bacteriologic cultures, direct skin contact, 
pipetting by mouth, inoculation, or spraying into the 
eyes, nose, or mouth), 2) performing work on an open 
bench (i.e., outside of biosafety level 3 containment 
equipment) with an open culture plate containing a 
Brucella isolate or being in close proximity to such 
work (e.g., across an open bench top or within 5 feet), 
or 3) presence in the laboratory during any procedure 
conducted on a Brucella isolate that might result in 
generation of aerosolized organisms and inhalational 
exposure (e.g., vortexing or catalase testing).
Errata: Vol. 59, No. 32
In the “Final 2009 Reports of Nationally 
Notifiable Infectious Diseases,” on page 1027, in 
“Table 2. Reported cases of notifiable diseases, by 
geographic division and area — United States, 2009,” 
the AIDS heading should read “HIV diagnoses.” On 
page 1030, under “Coccidioidomycosis,” the United 
States total should read “12,926,” and the totals for 
Pacific and California should read “2,488.”
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QuickStats 
FROM THE NATIONAL CENTER FOR HEALTH STATISTICS
Percentage of Adults Aged ≥18 Years Who Reported Vision Trouble,* by Sex 
and Age Group — National Health Interview Survey, 2009†
* Based on responses to the following questions: “Do you have any trouble seeing, even when wearing glasses 
or contact lenses?” and “Are you blind or unable to see at all?” For this analysis, “any trouble seeing” and “blind” 
were combined into one category.
† Estimates are based on household interviews of a sample of the civilian, noninstitutionalized U.S. population 
and are derived from the National Health Interview Survey sample adult component.
§ 95% confidence interval.
In 2009, women (9.3%) were more likely than men (7.2%) to report vision trouble. Among both men and women, adults aged 
≥75 years were most likely to report vision trouble, and adults aged 18–44 years were least likely to report vision trouble. Within 
each sex, rates of reported vision trouble were similar for persons aged 45–64 years and 65–74 years.
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TABLE I. Provisional cases of infrequently reported notifiable diseases (<1,000 cases reported during the preceding year) — United States, week ending 









Total cases reported 
for previous years States reporting cases 
during current week (No.)2009 2008 2007 2006 2005
Anthrax — — 0 1 — 1 1 —
Botulism, total 1 93 3 118 145 144 165 135
foodborne — 6 0 10 17 32 20 19
infant 1 66 2 83 109 85 97 85 WA (1)
other (wound and unspecified) — 21 1 25 19 27 48 31
Brucellosis — 114 2 115 80 131 121 120
Chancroid — 35 1 28 25 23 33 17
Cholera — 5 0 10 5 7 9 8
Cyclosporiasis§ — 166 1 141 139 93 137 543
Diphtheria — — — — — — — —
Domestic arboviral diseases § ,¶:
California serogroup virus disease — 65 0 55 62 55 67 80
Eastern equine encephalitis virus disease — 10 — 4 4 4 8 21
Powassan virus disease — 5 0 6 2 7 1 1
St. Louis encephalitis virus disease — 8 0 12 13 9 10 13
Western equine encephalitis virus disease — — — — — — — —
Haemophilus influenzae,** invasive disease (age <5 yrs):
serotype b — 14 0 35 30 22 29 9
nonserotype b 1 139 3 236 244 199 175 135 OK (1)
unknown serotype 4 232 3 178 163 180 179 217 FL (3), OK (1)
Hansen disease§ — 56 2 103 80 101 66 87
Hantavirus pulmonary syndrome§ — 17 1 20 18 32 40 26
Hemolytic uremic syndrome, postdiarrheal§ 2 208 4 242 330 292 288 221 TN (1), OK (1)
HIV infection, pediatric (age <13 yrs)†† — — 3 — — — — 380
Influenza-associated pediatric mortality§,§§ — 58 4 358 90 77 43 45
Listeriosis 7 713 17 851 759 808 884 896 NY (1), MD (1), WV (1), OK (2), CO (1), WA (1)
Measles¶¶ 1 59 0 71 140 43 55 66 CA (1)
Meningococcal disease, invasive***:
A, C, Y, and W-135 — 215 6 301 330 325 318 297
serogroup B — 99 3 174 188 167 193 156
other serogroup — 8 0 23 38 35 32 27
unknown serogroup 6 373 10 482 616 550 651 765 PA (1), GA (1), FL (1), CO (1), OR (1), CA (1)
Mumps 1 2,477 37 1,991 454 800 6,584 314 OH (1)
Novel influenza A virus infections††† — 3 0 43,774 2 4 NN NN
Plague — 2 — 8 3 7 17 8
Poliomyelitis, paralytic — — — 1 — — — 1
Polio virus Infection, nonparalytic§ — — — — — — NN NN
Psittacosis§ — 4 0 9 8 12 21 16
Q fever, total§,§§§ 1 111 1 114 120 171 169 136
acute 1 85 1 94 106 — — — CA (1)
chronic — 26 0 20 14 — — —
Rabies, human — 1 0 4 2 1 3 2
Rubella¶¶¶ — 6 0 3 16 12 11 11
Rubella, congenital syndrome — — — 2 — — 1 1
SARS-CoV§,**** — — — — — — — —
Smallpox§ — — — — — — — —
Streptococcal toxic-shock syndrome§ — 149 2 161 157 132 125 129
Syphilis, congenital (age <1 yr)†††† — 194 7 423 431 430 349 329
Tetanus — 7 1 18 19 28 41 27
Toxic-shock syndrome (staphylococcal)§ 2 72 1 74 71 92 101 90 GA (1), CA (1)
Trichinellosis — 5 0 13 39 5 15 16
Tularemia 2 101 1 93 123 137 95 154 CA (2)
Typhoid fever 5 381 4 397 449 434 353 324 MD (1), VA (1), NC (1), FL (1), CA (1)
Vancomycin-intermediate Staphylococcus aureus§ 2 84 1 78 63 37 6 2 NY (2)
Vancomycin-resistant Staphylococcus aureus§ — 1 — 1 — 2 1 3
Vibriosis (noncholera Vibrio species infections)§ 4 716 5 789 588 549 NN NN FL (2), CA (1), HI (1)
Viral hemorrhagic fever§§§§ — 1 — NN NN NN NN NN
Yellow fever — — — — — — — —
See Table I footnotes on next page.
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Notifiable Disease Data Team and 122 Cities Mortality Data Team
 Patsy A. Hall-Baker
Deborah A. Adams  Rosaline Dhara
Willie J. Anderson  Pearl C. Sharp
Michael S. Wodajo  Lenee Blanton
* Ratio of current 4-week total to mean of 15 4-week totals (from previous, comparable, and subsequent 4-week periods for the 
past 5 years). The point where the hatched area begins is based on the mean and two standard deviations of these 4-week 
totals.
FIGURE I. Selected notifiable disease reports, United States, comparison of provisional 4-week 



























TABLE I. (Continued) Provisional cases of infrequently reported notifiable diseases (<1,000 cases reported during the preceding year) — United States, week 
ending December 4, 2010 (48th week)*
—: No reported cases. N: Not reportable. NN: Not Nationally Notifiable Cum: Cumulative year-to-date counts.
 * Case counts for reporting year 2010 are provisional and subject to change. For further information on interpretation of these data, see http://www.cdc.gov/ncphi/disss/nndss/phs/files/
ProvisionalNationa%20NotifiableDiseasesSurveillanceData20100927.pdf.
 † Calculated by summing the incidence counts for the current week, the 2 weeks preceding the current week, and the 2 weeks following the current week, for a total of 5 preceding years. 
Additional information is available at http://www.cdc.gov/ncphi/disss/nndss/phs/files/5yearweeklyaverage.pdf.
 § Not reportable in all states. Data from states where the condition is not reportable are excluded from this table except starting in 2007 for the domestic arboviral diseases, STD data, TB 
data, and influenza-associated pediatric mortality, and in 2003 for SARS-CoV. Reporting exceptions are available at http://www.cdc.gov/ncphi/disss/nndss/phs/infdis.htm.
 ¶ Includes both neuroinvasive and nonneuroinvasive. Updated weekly from reports to the Division of Vector-Borne Infectious Diseases, National Center for Zoonotic, Vector-Borne, and 
Enteric Diseases (ArboNET Surveillance). Data for West Nile virus are available in Table II.
 ** Data for H. influenzae (all ages, all serotypes) are available in Table II.
 †† Updated monthly from reports to the Division of HIV/AIDS Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention. Implementation of HIV reporting influences 
the number of cases reported. Updates of pediatric HIV data have been temporarily suspended until upgrading of the national HIV/AIDS surveillance data management system is 
completed. Data for HIV/AIDS, when available, are displayed in Table IV, which appears quarterly.
 §§ Updated weekly from reports to the Influenza Division, National Center for Immunization and Respiratory Diseases. Since October 3, 2010, one influenza-associated pediatric death 
occurred during the 2010–11 influenza season. Since August 30, 2009, a total of 282 influenza-associated pediatric deaths occurring during the 2009–10 influenza season have been 
reported. 
 ¶¶ The one measles case reported for the current week was imported.
 *** Data for meningococcal disease (all serogroups) are available in Table II.
 ††† CDC discontinued reporting of individual confirmed and probable cases of 2009 pandemic influenza A (H1N1) virus infections on July 24, 2009. During 2009, four cases of human 
infection with novel influenza A viruses, different from the 2009 pandemic influenza A (H1N1) strain, were reported to CDC. The three cases of novel influenza A virus infection reported 
to CDC during 2010 were identified as swine influenza A (H3N2) virus and are unrelated to the 2009 pandemic influenza A (H1N1) virus. Total case counts for 2009 were provided by the 
Influenza Division, National Center for Immunization and Respiratory Diseases (NCIRD).
 §§§ In 2009, Q fever acute and chronic reporting categories were recognized as a result of revisions to the Q fever case definition. Prior to that time, case counts were not differentiated with 
respect to acute and chronic Q fever cases.
 ¶¶¶ No rubella cases were reported for the current week.
 **** Updated weekly from reports to the Division of Viral and Rickettsial Diseases, National Center for Zoonotic, Vector-Borne, and Enteric Diseases.
 †††† Updated weekly from reports to the Division of STD Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention.
 §§§§ There was one case of viral hemorrhagic fever reported during week 12. The one case report was confirmed as lassa fever. See Table II for dengue hemorrhagic fever.
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TABLE II. Provisional cases of selected notifiable diseases, United States, weeks ending December 4, 2010, and December 5, 2009 (48th week)*
Reporting area
Chlamydia trachomatis infection Cryptosporidiosis
Current  
week






Previous 52 weeks Cum  
2010
Cum  
2009Med Max Med Max
United States 11,987 23,850 26,342 1,112,919 1,151,894 64 120 342 7,123 6,917
New England 731 759 1,396 37,043 37,042 2 7 77 425 432
Connecticut 122 198 736 9,389 10,594 — 0 71 71 38
Maine† — 49 69 1,996 2,250 — 1 7 74 47
Massachusetts 408 399 695 19,020 17,717 — 3 8 148 169
New Hampshire 60 43 114 2,283 1,971 — 1 5 51 79
Rhode Island† 118 64 120 3,206 3,394 — 0 2 13 22
Vermont† 23 23 51 1,149 1,116 2 1 5 68 77
Mid. Atlantic 1,895 3,375 5,027 158,925 146,305 5 15 38 785 778
New Jersey 519 516 691 24,908 22,686 — 1 4 36 51
New York (Upstate) 826 687 2,530 32,372 29,124 5 3 16 202 202
New York City — 1,213 2,738 57,635 54,555 — 2 5 93 80
Pennsylvania 550 933 1,092 44,010 39,940 — 8 26 454 445
E.N. Central 721 3,486 4,127 161,641 184,912 6 30 122 1,903 1,628
Illinois 11 761 1,225 35,060 56,746 — 4 21 265 149
Indiana — 372 797 17,664 20,521 — 3 10 143 269
Michigan 460 923 1,419 44,444 42,908 1 5 18 300 270
Ohio 143 981 1,085 44,932 45,161 5 7 24 431 363
Wisconsin 107 424 512 19,541 19,576 — 9 57 764 577
W.N. Central 189 1,360 1,565 62,928 65,826 9 22 83 1,241 1,050
Iowa 15 202 270 9,479 8,842 — 4 24 316 198
Kansas 28 189 235 8,814 9,905 4 2 9 130 100
Minnesota — 282 340 12,259 13,387 — 0 16 98 321
Missouri 116 503 616 23,774 24,105 2 4 30 357 177
Nebraska† — 93 237 4,198 5,081 2 2 26 222 114
North Dakota 9 30 89 1,532 1,734 1 0 18 31 12
South Dakota 21 62 77 2,872 2,772 — 2 6 87 128
S. Atlantic 3,762 4,736 5,681 223,144 233,333 16 18 51 940 1,069
Delaware 99 84 220 4,094 4,364 — 0 2 7 10
District of Columbia — 91 177 4,387 6,258 — 0 1 5 7
Florida 700 1,469 1,737 68,802 68,203 12 7 19 357 430
Georgia 221 622 1,229 29,717 37,533 3 5 31 279 322
Maryland† 677 453 1,031 21,448 21,090 — 1 3 33 41
North Carolina 686 765 1,562 37,241 38,231 — 0 12 73 108
South Carolina† 590 524 748 25,294 25,055 — 1 8 82 58
Virginia† 721 596 902 28,599 29,188 1 2 8 88 77
West Virginia 68 73 117 3,562 3,411 — 0 3 16 16
E.S. Central 437 1,746 2,414 80,542 86,741 1 4 19 304 216
Alabama† — 495 757 23,968 24,418 — 2 13 150 62
Kentucky 337 264 614 13,395 12,174 — 1 6 79 62
Mississippi — 377 780 17,518 22,252 — 0 3 22 18
Tennessee† 100 573 747 25,661 27,897 1 1 5 53 74
W.S. Central 1,347 3,016 4,582 147,448 149,303 2 7 39 405 533
Arkansas† 286 268 392 11,452 13,457 — 0 3 31 54
Louisiana 210 286 1,731 15,385 25,516 — 1 6 60 53
Oklahoma — 261 1,374 13,728 13,147 2 1 8 80 120
Texas† 851 2,222 3,194 106,883 97,183 — 4 30 234 306
Mountain 931 1,455 1,912 70,019 73,891 2 10 29 518 535
Arizona 321 515 713 24,290 23,823 — 1 3 35 33
Colorado 185 359 560 16,009 18,401 1 2 8 129 133
Idaho† 82 69 200 3,654 3,516 1 2 7 89 90
Montana† — 60 82 2,733 2,780 — 1 4 46 53
Nevada† 159 172 337 8,545 9,286 — 0 6 31 25
New Mexico† 184 162 453 7,411 8,505 — 2 12 113 140
Utah — 121 176 5,630 5,730 — 1 5 59 39
Wyoming† — 36 79 1,747 1,850 — 0 2 16 22
Pacific 1,974 3,658 5,350 171,229 174,541 21 12 28 602 676
Alaska — 113 148 5,224 4,804 — 0 1 5 6
California 1,397 2,806 4,406 131,258 133,700 14 8 18 353 408
Hawaii 1 112 158 5,361 5,657 — 0 1 1 1
Oregon 282 212 468 10,500 10,423 1 3 13 166 179
Washington 294 399 500 18,886 19,957 6 1 8 77 82
Territories
American Samoa — 0 0 — — N 0 0 N N
C.N.M.I. — — — — — — — — — —
Guam — 7 31 259 327 — 0 0 — —
Puerto Rico — 92 265 4,950 6,765 N 0 0 N N
U.S. Virgin Islands — 11 29 323 469 — 0 0 — —
C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable.   —: No reported cases.   N: Not reportable.   NN: Not Nationally Notifiable.   Cum: Cumulative year-to-date counts.   Med: Median.   Max: Maximum.
* Case counts for reporting year 2010 are provisional and subject to change. For further information on interpretation of these data, see http://www.cdc.gov/ncphi/disss/nndss/phs/files/
ProvisionalNationa%20NotifiableDiseasesSurveillanceData20100927.pdf. Data for HIV/AIDS, AIDS and TB, when available, are displayed in Table IV, which appears quarterly.
† Contains data reported through the National Electronic Disease Surveillance System (NEDSS).
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TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending December 4, 2010, and December 5, 2009 (48th week)*
Dengue Virus Infection
Reporting area
Dengue Fever† Dengue Hemorrhagic Fever§
Current  
week






Previous 52 weeks Cum  
2010
Cum  
2009Med Max Med Max
United States — 6 36 459 NN — 0 2 5 NN
New England — 0 3 8 NN — 0 0 — NN
Connecticut — 0 0 — NN — 0 0 — NN
Maine¶ — 0 2 5 NN — 0 0 — NN
Massachusetts — 0 0 — NN — 0 0 — NN
New Hampshire — 0 0 — NN — 0 0 — NN
Rhode Island¶ — 0 0 — NN — 0 0 — NN
Vermont¶ — 0 1 3 NN — 0 0 — NN
Mid. Atlantic — 2 12 132 NN — 0 1 1 NN
New Jersey — 0 0 — NN — 0 0 — NN
New York (Upstate) — 0 0 — NN — 0 0 — NN
New York City — 1 12 115 NN — 0 1 1 NN
Pennsylvania — 0 2 17 NN — 0 0 — NN
E.N. Central — 0 5 41 NN — 0 1 1 NN
Illinois — 0 0 — NN — 0 0 — NN
Indiana — 0 2 11 NN — 0 0 — NN
Michigan — 0 2 9 NN — 0 0 — NN
Ohio — 0 2 16 NN — 0 0 — NN
Wisconsin — 0 2 5 NN — 0 1 1 NN
W.N. Central — 0 2 17 NN — 0 0 — NN
Iowa — 0 1 2 NN — 0 0 — NN
Kansas — 0 1 1 NN — 0 0 — NN
Minnesota — 0 2 13 NN — 0 0 — NN
Missouri — 0 0 — NN — 0 0 — NN
Nebraska¶ — 0 0 — NN — 0 0 — NN
North Dakota — 0 1 1 NN — 0 0 — NN
South Dakota — 0 0 — NN — 0 0 — NN
S. Atlantic — 2 17 213 NN — 0 1 2 NN
Delaware — 0 0 — NN — 0 0 — NN
District of Columbia — 0 0 — NN — 0 0 — NN
Florida — 2 14 174 NN — 0 1 2 NN
Georgia — 0 2 11 NN — 0 0 — NN
Maryland¶ — 0 0 — NN — 0 0 — NN
North Carolina — 0 1 4 NN — 0 0 — NN
South Carolina¶ — 0 3 10 NN — 0 0 — NN
Virginia¶ — 0 3 12 NN — 0 0 — NN
West Virginia — 0 1 2 NN — 0 0 — NN
E.S. Central — 0 2 5 NN — 0 0 — NN
Alabama¶ — 0 2 2 NN — 0 0 — NN
Kentucky — 0 1 1 NN — 0 0 — NN
Mississippi — 0 1 1 NN — 0 0 — NN
Tennessee¶ — 0 1 1 NN — 0 0 — NN
W.S. Central — 0 1 4 NN — 0 1 1 NN
Arkansas¶ — 0 0 — NN — 0 1 1 NN
Louisiana — 0 0 — NN — 0 0 — NN
Oklahoma — 0 1 4 NN — 0 0 — NN
Texas¶ — 0 0 — NN — 0 0 — NN
Mountain — 0 2 16 NN — 0 0 — NN
Arizona — 0 1 6 NN — 0 0 — NN
Colorado — 0 0 — NN — 0 0 — NN
Idaho¶ — 0 1 2 NN — 0 0 — NN
Montana¶ — 0 1 3 NN — 0 0 — NN
Nevada¶ — 0 1 4 NN — 0 0 — NN
New Mexico¶ — 0 1 1 NN — 0 0 — NN
Utah — 0 0 — NN — 0 0 — NN
Wyoming¶ — 0 0 — NN — 0 0 — NN
Pacific — 0 5 23 NN — 0 0 — NN
Alaska — 0 0 — NN — 0 0 — NN
California — 0 5 11 NN — 0 0 — NN
Hawaii — 0 0 — NN — 0 0 — NN
Oregon — 0 0 — NN — 0 0 — NN
Washington — 0 2 12 NN — 0 0 — NN
Territories
American Samoa — 0 0 — NN — 0 0 — NN
C.N.M.I. — — — — NN — — — — NN
Guam — 0 0 — NN — 0 0 — NN
Puerto Rico — 109 535 9,692 NN — 0 3 37 NN
U.S. Virgin Islands — 0 0 — NN — 0 0 — NN
C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable.   —: No reported cases.   N: Not reportable.   NN: Not Nationally Notifiable.   Cum: Cumulative year-to-date counts.   Med: Median.   Max: Maximum.
* Case counts for reporting year 2010 are provisional and subject to change. For further information on interpretation of these data, see http://www.cdc.gov/ncphi/disss/nndss/phs/files/
ProvisionalNationa%20NotifiableDiseasesSurveillanceData20100927.pdf. Data for HIV/AIDS, AIDS and TB, when available, are displayed in Table IV, which appears quarterly.
† Dengue Fever includes cases that meet criteria for Dengue Fever with hemorrhage, other clinical, and unknown case classifications. 
§ DHF includes cases that meet criteria for dengue shock syndrome (DSS), a more severe form of DHF.
¶ Contains data reported through the National Electronic Disease Surveillance System (NEDSS).
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TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending December 4, 2010, and December 5, 2009 (48th week)*
Ehrlichiosis/Anaplasmosis†
Reporting area
Ehrlichia chaffeensis Anaplasma phagocytophilum Undetermined
Current 
week












Previous 52 weeks Cum 
2010
Cum 
2009Med Max Med Max Med Max
United States 3 8 181 574 900 10 11 309 747 899 — 1 35 98 164
New England — 0 2 6 52 — 1 8 81 261 — 0 2 8 2
Connecticut — 0 0 — — — 0 5 25 17 — 0 2 6 —
Maine§ — 0 1 4 5 — 0 2 16 14 — 0 0 — —
Massachusetts — 0 0 — 9 — 0 2 — 97 — 0 0 — —
New Hampshire — 0 1 2 4 — 0 3 16 19 — 0 1 2 1
Rhode Island§ — 0 1 — 33 — 0 7 24 114 — 0 0 — 1
Vermont§ — 0 0 — 1 — 0 0 — — — 0 0 — —
Mid. Atlantic 1 1 15 50 189 10 3 17 206 303 — 0 2 4 44
New Jersey — 0 2 — 100 — 0 1 1 70 — 0 0 — —
New York (Upstate) 1 0 15 29 53 10 3 17 202 222 — 0 1 4 6
New York City — 0 3 20 10 — 0 1 3 9 — 0 0 — 1
Pennsylvania — 0 1 1 26 — 0 1 — 2 — 0 1 — 37
E.N. Central — 0 4 32 84 — 4 39 365 277 — 1 7 61 71
Illinois — 0 2 12 33 — 0 2 7 6 — 0 2 3 3
Indiana — 0 0 — — — 0 0 — — — 0 3 28 36
Michigan — 0 1 2 6 — 0 0 — — — 0 1 4 —
Ohio — 0 3 6 13 — 0 1 2 1 — 0 0 — 2
Wisconsin — 0 1 12 32 — 4 39 356 270 — 0 4 26 30
W.N. Central — 1 13 123 153 — 0 261 14 35 — 0 30 11 20
Iowa — 0 0 — — — 0 0 — — — 0 0 — —
Kansas — 0 1 6 6 — 0 0 — 1 — 0 0 — —
Minnesota — 0 6 — 2 — 0 261 — 29 — 0 30 — 7
Missouri — 1 13 115 143 — 0 3 14 4 — 0 3 11 13
Nebraska§ — 0 1 2 2 — 0 0 — 1 — 0 0 — —
North Dakota — 0 0 — — — 0 0 — — — 0 0 — —
South Dakota — 0 0 — — — 0 0 — — — 0 0 — —
S. Atlantic — 4 19 247 255 — 1 7 57 17 — 0 2 7 2
Delaware — 0 3 17 22 — 0 1 4 2 — 0 0 — —
District of Columbia — 0 0 — — — 0 0 — — — 0 0 — —
Florida — 0 2 8 12 — 0 1 3 3 — 0 0 — —
Georgia — 0 4 22 18 — 0 1 2 1 — 0 1 1 —
Maryland§ — 0 3 24 42 — 0 2 15 4 — 0 2 3 —
North Carolina — 2 13 100 61 — 0 4 21 3 — 0 0 — —
South Carolina§ — 0 2 3 12 — 0 1 1 — — 0 0 — —
Virginia§ — 1 13 72 87 — 0 2 11 4 — 0 1 3 2
West Virginia — 0 1 1 1 — 0 0 — — — 0 1 — —
E.S. Central — 1 10 85 134 — 0 2 18 3 — 0 1 6 24
Alabama§ — 0 3 11 9 — 0 2 7 1 — 0 0 — —
Kentucky — 0 2 16 12 — 0 0 — — — 0 0 — —
Mississippi — 0 1 3 6 — 0 1 1 — — 0 0 — —
Tennessee§ — 0 6 55 107 — 0 2 10 2 — 0 1 6 24
W.S. Central 2 0 141 30 30 — 0 23 6 1 — 0 1 1 —
Arkansas§ 2 0 34 11 4 — 0 6 3 — — 0 0 — —
Louisiana — 0 1 1 — — 0 0 — — — 0 0 — —
Oklahoma — 0 105 15 24 — 0 16 2 1 — 0 0 — —
Texas§ — 0 2 3 2 — 0 1 1 — — 0 1 1 —
Mountain — 0 0 — — — 0 0 — — — 0 0 — 1
Arizona — 0 0 — — — 0 0 — — — 0 0 — 1
Colorado — 0 0 — — — 0 0 — — — 0 0 — —
Idaho§ — 0 0 — — — 0 0 — — — 0 0 — —
Montana§ — 0 0 — — — 0 0 — — — 0 0 — —
Nevada§ — 0 0 — — — 0 0 — — — 0 0 — —
New Mexico§ — 0 0 — — — 0 0 — — — 0 0 — —
Utah — 0 0 — — — 0 0 — — — 0 0 — —
Wyoming§ — 0 0 — — — 0 0 — — — 0 0 — —
Pacific — 0 1 1 3 — 0 0 — 2 — 0 1 — —
Alaska — 0 0 — — — 0 0 — — — 0 0 — —
California — 0 1 1 3 — 0 0 — 2 — 0 1 — —
Hawaii — 0 0 — — — 0 0 — — — 0 0 — —
Oregon — 0 0 — — — 0 0 — — — 0 0 — —
Washington — 0 0 — — — 0 0 — — — 0 0 — —
Territories
American Samoa — 0 0 — — — 0 0 — — — 0 0 — —
C.N.M.I. — — — — — — — — — — — — — — —
Guam — 0 0 — — — 0 0 — — — 0 0 — —
Puerto Rico — 0 0 — — — 0 0 — — — 0 0 — —
U.S. Virgin Islands — 0 0 — — — 0 0 — — — 0 0 — —
C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable.   —: No reported cases.   N: Not reportable.   NN: Not Nationally Notifiable.   Cum: Cumulative year-to-date counts.   Med: Median.   Max: Maximum.
* Case counts for reporting year 2010 are provisional and subject to change. For further information on interpretation of these data, see http://www.cdc.gov/ncphi/disss/nndss/phs/files/
ProvisionalNationa%20NotifiableDiseasesSurveillanceData20100927.pdf. Data for HIV/AIDS, AIDS and TB, when available, are displayed in Table IV, which appears quarterly.
† Cumulative total E. ewingii cases reported for year 2010 = 10.
§ Contains data reported through the National Electronic Disease Surveillance System (NEDSS).
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TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending December 4, 2010, and December 5, 2009 (48th week)*
Reporting area
Giardiasis Gonorrhea
Haemophilus influenzae, invasive†  
All ages, all serotypes
Current 
week












Previous 52 weeks Cum 
2010
Cum 
2009Med Max Med Max Med Max
United States 200 341 666 16,460 17,749 2,918 5,565 6,382 260,808 279,857 45 59 171 2,664 2,629
New England 10 31 54 1,458 1,641 183 102 196 4,981 4,616 3 3 21 171 179
Connecticut — 5 13 236 273 116 39 169 2,151 2,220 3 0 15 43 48
Maine§ 6 4 12 215 200 — 3 11 136 128 — 0 2 11 19
Massachusetts — 13 24 637 707 62 46 81 2,234 1,812 — 2 8 86 86
New Hampshire 1 3 8 135 190 4 3 7 147 105 — 0 2 11 12
Rhode Island§ — 1 7 60 60 1 5 14 266 307 — 0 2 11 9
Vermont§ 3 4 10 175 211 — 0 17 47 44 — 0 1 9 5
Mid. Atlantic 46 63 103 2,956 3,211 397 688 1,157 33,636 29,313 7 11 34 531 536
New Jersey — 6 14 293 404 129 112 176 5,503 4,470 — 2 7 84 118
New York (Upstate) 27 22 84 1,094 1,239 110 104 422 5,367 5,380 6 3 20 148 145
New York City 8 17 33 855 774 — 230 528 11,058 10,246 — 2 6 102 68
Pennsylvania 11 14 27 714 794 158 249 366 11,708 9,217 1 4 9 197 205
E.N. Central 25 54 83 2,640 2,731 240 942 1,260 44,428 59,011 5 10 20 443 413
Illinois — 12 26 532 576 8 186 366 8,357 18,795 — 3 9 136 155
Indiana — 5 14 207 285 — 99 222 4,999 6,481 — 1 6 75 75
Michigan 3 13 25 629 620 142 249 471 12,283 13,904 — 0 3 32 24
Ohio 21 16 29 806 764 64 318 380 14,424 14,963 5 2 6 110 91
Wisconsin 1 8 32 466 486 26 93 155 4,365 4,868 — 2 5 90 68
W.N. Central 13 24 165 1,321 1,751 55 280 357 13,106 13,905 6 3 24 154 151
Iowa 1 5 11 267 276 7 33 57 1,620 1,570 — 0 1 1 —
Kansas 1 4 10 199 152 7 37 62 1,813 2,367 — 0 2 15 13
Minnesota — 0 135 136 539 — 38 62 1,734 2,155 — 0 17 25 54
Missouri 5 8 26 404 487 41 137 178 6,430 6,066 3 1 6 79 56
Nebraska§ 6 4 9 207 162 — 20 50 995 1,293 3 0 2 24 22
North Dakota — 0 7 29 25 — 2 11 102 133 — 0 4 10 6
South Dakota — 1 7 79 110 — 8 19 412 321 — 0 0 — —
S. Atlantic 42 71 143 3,389 3,463 1,052 1,348 1,787 64,705 69,777 15 14 27 696 712
Delaware — 0 5 30 25 17 18 48 916 891 — 0 1 5 4
District of Columbia — 1 5 35 70 — 33 66 1,647 2,446 — 0 1 4 5
Florida 34 39 87 1,973 1,800 242 392 493 18,581 19,537 8 3 9 177 207
Georgia — 9 51 485 701 79 211 421 9,888 12,829 2 3 9 162 139
Maryland§ 2 5 11 246 264 206 132 237 6,276 5,748 3 1 6 63 81
North Carolina N 0 0 N N 222 246 596 12,473 12,950 1 2 9 114 97
South Carolina§ — 2 9 124 102 129 152 232 7,450 7,846 — 2 7 72 70
Virginia§ 3 9 36 451 449 144 152 265 6,947 7,081 — 2 4 72 82
West Virginia 3 0 6 45 52 13 10 26 527 449 1 0 5 27 27
E.S. Central 5 6 15 265 386 98 465 697 21,901 24,893 — 3 12 156 153
Alabama§ 5 4 11 208 185 — 146 217 6,976 7,041 — 0 3 24 36
Kentucky N 0 0 N N 77 72 142 3,475 3,517 — 1 2 32 19
Mississippi N 0 0 N N — 110 216 5,036 6,890 — 0 2 11 8
Tennessee§ — 1 9 57 201 21 137 194 6,414 7,445 — 2 10 89 90
W.S. Central 3 8 16 355 482 402 830 1,303 40,080 43,639 5 2 20 123 116
Arkansas§ 2 2 7 125 141 82 77 133 3,510 4,197 — 0 3 16 20
Louisiana 1 3 9 167 188 93 86 508 4,461 8,300 — 0 4 24 20
Oklahoma — 2 7 63 153 — 78 359 4,041 4,166 5 1 15 75 72
Texas§ N 0 0 N N 227 582 964 28,068 26,976 — 0 2 8 4
Mountain 10 30 50 1,509 1,556 139 180 262 8,332 8,663 4 5 15 269 229
Arizona — 3 8 146 194 43 63 109 2,864 2,904 — 2 10 97 75
Colorado 7 13 27 652 468 28 53 95 2,482 2,606 2 1 5 77 63
Idaho§ 2 4 9 191 196 13 2 7 121 98 1 0 2 18 4
Montana§ — 2 7 97 127 — 2 6 95 73 — 0 1 2 1
Nevada§ 1 1 11 96 102 28 29 94 1,485 1,590 1 0 2 9 18
New Mexico§ — 2 5 92 110 27 20 41 981 998 — 1 5 39 33
Utah — 4 11 199 295 — 5 15 275 324 — 0 4 21 32
Wyoming§ — 1 5 36 64 — 0 4 29 70 — 0 2 6 3
Pacific 46 53 133 2,567 2,528 352 606 815 29,639 26,040 — 2 21 121 140
Alaska — 2 6 88 106 — 24 37 1,128 908 — 0 2 20 20
California 32 33 61 1,592 1,657 294 497 691 24,366 21,392 — 0 18 22 40
Hawaii — 0 4 33 20 4 14 25 693 592 — 0 2 9 28
Oregon 2 9 20 441 381 9 19 42 928 1,016 — 1 5 64 49
Washington 12 8 75 413 364 45 52 80 2,524 2,132 — 0 4 6 3
Territories
American Samoa — 0 0 — — — 0 0 — — — 0 0 — —
C.N.M.I. — — — — — — — — — — — — — — —
Guam — 0 1 2 3 — 0 4 30 19 — 0 0 — —
Puerto Rico — 1 8 65 147 — 6 14 274 216 — 0 1 1 4
U.S. Virgin Islands — 0 0 — — — 2 7 78 114 — 0 0 — —
C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable.   —: No reported cases.   N: Not reportable.   NN: Not Nationally Notifiable.   Cum: Cumulative year-to-date counts.   Med: Median.   Max: Maximum.
* Case counts for reporting year 2010 are provisional and subject to change. For further information on interpretation of these data, see http://www.cdc.gov/ncphi/disss/nndss/phs/files/
ProvisionalNationa%20NotifiableDiseasesSurveillanceData20100927.pdf. Data for HIV/AIDS, AIDS and TB, when available, are displayed in Table IV, which appears quarterly.
† Data for H. influenzae (age <5 yrs for serotype b, nonserotype b, and unknown serotype) are available in Table I.
§ Contains data reported through the National Electronic Disease Surveillance System (NEDSS).
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TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending December 4, 2010, and December 5, 2009 (48th week)*

















Previous 52 weeks Cum 
2010
Cum 
2009Med Max Med Max Med Max
United States 23 30 69 1,420 1,823 28 63 204 2,854 2,997 7 14 44 753 699
New England — 2 5 85 103 — 1 5 48 51 — 1 4 39 63
Connecticut — 0 3 27 18 — 0 2 19 15 — 0 4 27 50
Maine† — 0 1 7 1 — 0 2 13 15 — 0 0 — 2
Massachusetts — 1 5 41 67 — 0 2 8 17 — 0 1 10 10
New Hampshire — 0 1 2 7 — 0 2 6 4 N 0 0 N N
Rhode Island† — 0 4 8 8 U 0 0 U U U 0 0 U U
Vermont† — 0 0 — 2 — 0 1 2 — — 0 1 2 1
Mid. Atlantic 3 4 10 193 252 2 5 10 260 308 1 2 6 102 94
New Jersey — 0 3 14 61 — 1 5 66 91 — 0 2 14 7
New York (Upstate) 2 1 4 57 44 2 1 6 51 47 — 1 4 56 44
New York City — 1 5 70 83 — 2 4 77 67 — 0 1 1 5
Pennsylvania 1 1 4 52 64 — 1 5 66 103 1 0 3 31 38
E.N. Central 2 4 9 200 275 1 9 17 425 404 1 2 8 109 84
Illinois — 1 3 44 122 — 1 5 80 114 — 0 1 2 4
Indiana — 0 2 17 16 — 1 5 50 68 — 0 2 21 19
Michigan 1 1 5 67 71 1 3 6 116 118 1 1 5 70 32
Ohio 1 1 5 46 35 — 2 6 85 82 — 0 1 8 26
Wisconsin — 0 3 26 31 — 2 8 94 22 — 0 2 8 3
W.N. Central — 1 13 74 111 1 2 15 110 131 — 0 11 24 22
Iowa — 0 3 11 35 — 0 2 13 34 — 0 1 — 10
Kansas — 0 3 12 12 — 0 2 8 6 — 0 2 3 1
Minnesota — 0 12 15 19 — 0 13 8 24 — 0 9 12 6
Missouri — 0 2 23 21 1 1 3 68 43 — 0 1 7 —
Nebraska† — 0 4 12 20 — 0 2 12 21 — 0 1 2 3
North Dakota — 0 1 — 1 — 0 0 — — — 0 1 — 1
South Dakota — 0 1 1 3 — 0 1 1 3 — 0 0 — 1
S. Atlantic 3 7 14 321 399 8 17 40 811 819 3 4 7 162 163
Delaware — 0 1 7 4 — 0 2 23 31 U 0 0 U U
District of Columbia — 0 1 1 1 — 0 1 3 10 — 0 1 2 1
Florida 2 3 7 132 162 5 6 11 278 272 2 1 5 54 48
Georgia — 1 3 35 48 1 3 7 138 136 — 0 2 9 31
Maryland† — 0 3 23 45 — 1 6 70 69 1 0 3 26 22
North Carolina — 0 5 45 36 — 1 16 91 99 — 1 3 40 22
South Carolina† — 0 3 22 60 — 1 4 53 53 — 0 1 1 1
Virginia† 1 1 6 48 38 2 2 14 93 88 — 0 2 13 10
West Virginia — 0 5 8 5 — 0 14 62 61 — 0 5 17 28
E.S. Central 2 1 3 41 39 5 7 13 334 318 — 3 8 143 98
Alabama† 2 0 1 8 11 — 1 4 61 82 — 0 1 6 8
Kentucky — 0 3 19 10 — 2 8 121 83 — 2 6 99 59
Mississippi — 0 1 2 8 — 1 3 34 31 U 0 0 U U
Tennessee† — 0 2 12 10 5 2 8 118 122 — 1 4 38 31
W.S. Central 5 3 19 134 181 8 9 109 456 534 2 1 14 69 54
Arkansas† — 0 1 2 11 — 0 4 41 61 — 0 0 — 2
Louisiana — 0 2 12 6 — 1 4 45 66 — 0 1 9 8
Oklahoma — 0 3 1 6 2 2 19 89 98 2 0 12 30 12
Texas† 5 2 18 119 158 6 5 87 281 309 — 0 3 30 32
Mountain — 3 8 135 151 1 3 8 128 123 — 1 5 50 49
Arizona — 1 5 60 63 — 1 2 30 40 U 0 0 U U
Colorado — 1 3 34 47 — 0 5 40 25 — 0 1 12 26
Idaho† — 0 2 7 5 — 0 1 6 11 — 0 2 9 6
Montana† — 0 1 4 6 — 0 1 1 1 — 0 1 2 1
Nevada† — 0 2 14 13 1 1 3 38 31 — 0 1 6 4
New Mexico† — 0 1 5 8 — 0 1 5 6 — 0 2 11 6
Utah — 0 1 8 7 — 0 1 5 5 — 0 2 10 6
Wyoming† — 0 3 3 2 — 0 1 3 4 — 0 0 — —
Pacific 8 5 17 237 312 2 6 20 282 309 — 1 6 55 72
Alaska — 0 1 3 2 — 0 1 3 4 U 0 0 U U
California 8 4 16 195 247 2 4 17 198 219 — 0 4 22 38
Hawaii — 0 2 4 8 — 0 1 3 6 U 0 0 U U
Oregon — 0 2 17 16 — 1 3 35 40 — 0 3 14 17
Washington — 0 2 18 39 — 1 4 43 40 — 0 6 19 15
Territories
American Samoa — 0 0 — — — 0 0 — — — 0 0 — —
C.N.M.I. — — — — — — — — — — — — — — —
Guam — 0 6 18 6 — 1 6 40 54 — 1 7 35 48
Puerto Rico — 0 2 13 21 — 0 2 18 32 — 0 0 — —
U.S. Virgin Islands — 0 0 — — — 0 0 — — — 0 0 — —
C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable.   —: No reported cases.   N: Not reportable.   NN: Not Nationally Notifiable.   Cum: Cumulative year-to-date counts.   Med: Median.   Max: Maximum.
* Case counts for reporting year 2010 are provisional and subject to change. For further information on interpretation of these data, see http://www.cdc.gov/ncphi/disss/nndss/phs/files/
ProvisionalNationa%20NotifiableDiseasesSurveillanceData20100927.pdf. Data for HIV/AIDS, AIDS and TB, when available, are displayed in Table IV, which appears quarterly.
† Contains data reported through the National Electronic Disease Surveillance System (NEDSS).
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TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending December 4, 2010, and December 5, 2009 (48th week)*
Reporting area
Legionellosis Lyme disease Malaria
Current 
week












Previous 52 weeks Cum 
2010
Cum 
2009Med Max Med Max Med Max
United States 41 57 114 2,951 3,259 130 403 2,336 25,873 35,247 16 27 89 1,357 1,290
New England 2 3 15 217 186 28 119 478 7,632 12,070 — 2 4 65 56
Connecticut 2 0 6 49 51 — 41 204 2,539 4,077 — 0 1 1 5
Maine† — 0 4 12 8 25 11 76 673 854 — 0 1 5 2
Massachusetts — 1 8 103 88 — 37 206 2,763 5,144 — 1 3 45 36
New Hampshire — 0 5 21 13 1 23 67 1,178 1,373 — 0 2 4 4
Rhode Island† — 0 4 23 19 — 1 40 149 228 — 0 1 7 5
Vermont† — 0 2 9 7 2 4 27 330 394 — 0 1 3 4
Mid. Atlantic 16 14 44 810 1,136 59 177 726 11,868 15,351 2 7 17 368 382
New Jersey — 2 11 93 210 — 46 212 3,100 4,879 — 0 4 1 95
New York (Upstate) 9 5 19 271 336 38 52 577 2,745 3,862 2 1 6 70 45
New York City — 2 14 140 220 — 1 14 67 1,020 — 4 14 242 190
Pennsylvania 7 5 18 306 370 21 82 383 5,956 5,590 — 1 3 55 52
E.N. Central 8 11 41 653 688 7 14 270 2,298 2,920 1 3 9 137 163
Illinois — 1 15 120 125 — 1 17 123 136 — 1 7 51 68
Indiana — 2 6 102 60 — 1 7 69 81 — 0 2 8 23
Michigan 1 3 20 165 159 — 1 13 91 99 — 0 4 29 28
Ohio 7 4 15 220 270 7 0 5 34 55 1 0 5 39 35
Wisconsin — 0 11 46 74 — 12 243 1,981 2,549 — 0 1 10 9
W.N. Central 1 1 19 104 114 — 2 1,395 115 261 — 1 11 67 64
Iowa — 0 1 — 23 — 1 10 80 106 — 0 2 13 10
Kansas — 0 2 11 7 — 0 1 6 18 — 0 2 11 8
Minnesota — 0 16 35 12 — 0 1,380 — 128 — 0 11 3 24
Missouri — 0 4 33 57 — 0 1 1 3 — 0 3 21 12
Nebraska† — 0 2 9 12 — 0 2 9 5 — 0 2 15 8
North Dakota 1 0 1 7 1 — 0 15 18 — — 0 1 1 1
South Dakota — 0 2 9 2 — 0 1 1 1 — 0 2 3 1
S. Atlantic 6 10 27 505 556 33 59 175 3,594 4,180 3 7 42 390 341
Delaware 1 0 3 16 19 2 11 32 600 950 — 0 1 2 5
District of Columbia — 0 4 15 23 — 0 4 27 61 — 0 2 9 17
Florida 4 3 9 163 175 3 2 10 97 105 3 2 7 123 84
Georgia — 1 4 52 58 — 0 2 11 40 — 0 5 45 66
Maryland† 1 2 6 108 143 9 24 100 1,553 1,976 — 1 22 93 75
North Carolina — 0 7 53 58 — 1 9 80 93 — 0 13 47 30
South Carolina† — 0 2 10 12 — 0 3 28 41 — 0 1 4 5
Virginia† — 1 8 74 59 19 18 79 1,077 750 — 1 5 64 57
West Virginia — 0 3 14 9 — 0 32 121 164 — 0 2 3 2
E.S. Central 1 2 10 124 137 — 1 4 44 36 1 0 3 30 31
Alabama† — 0 2 18 17 — 0 1 2 3 — 0 1 9 9
Kentucky — 0 4 26 52 — 0 1 5 1 1 0 3 7 9
Mississippi — 0 3 10 4 — 0 0 — — — 0 2 2 4
Tennessee† 1 1 6 70 64 — 0 4 37 32 — 0 2 12 9
W.S. Central 2 3 14 139 123 — 2 44 94 216 — 1 31 77 64
Arkansas† 1 0 2 15 8 — 0 0 — — — 0 1 2 5
Louisiana — 0 3 8 14 — 0 1 2 — — 0 1 5 6
Oklahoma — 0 4 13 6 — 0 2 — — — 0 1 5 1
Texas† 1 2 10 103 95 — 2 42 92 216 — 1 30 65 52
Mountain 1 3 10 155 138 — 0 3 24 54 1 1 4 58 47
Arizona — 1 6 59 43 — 0 1 2 6 — 0 2 22 10
Colorado — 0 5 32 27 — 0 1 3 1 1 0 3 21 26
Idaho† 1 0 1 7 7 — 0 2 7 15 — 0 1 3 2
Montana† — 0 1 4 7 — 0 1 4 3 — 0 1 2 5
Nevada† — 0 2 19 13 — 0 1 1 12 — 0 1 6 —
New Mexico† — 0 2 9 9 — 0 2 5 5 — 0 1 1 —
Utah — 0 2 20 28 — 0 1 2 9 — 0 1 3 4
Wyoming† — 0 2 5 4 — 0 1 — 3 — 0 0 — —
Pacific 4 5 19 244 181 3 4 11 204 159 8 3 19 165 142
Alaska — 0 2 2 1 — 0 1 6 7 — 0 1 3 2
California 4 4 19 204 140 3 3 9 136 100 4 2 13 112 107
Hawaii — 0 1 1 1 N 0 0 N N — 0 1 1 1
Oregon — 0 3 14 16 — 1 4 49 37 — 0 3 14 11
Washington — 0 4 23 23 — 0 3 13 15 4 0 5 35 21
Territories
American Samoa — 0 0 — — N 0 0 N N — 0 0 — —
C.N.M.I. — — — — — — — — — — — — — — —
Guam — 0 1 1 — — 0 0 — — — 0 0 — —
Puerto Rico — 0 1 — 2 N 0 0 N N — 0 2 4 5
U.S. Virgin Islands — 0 0 — — — 0 0 — — — 0 0 — —
C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable.   —: No reported cases.   N: Not reportable.   NN: Not Nationally Notifiable.   Cum: Cumulative year-to-date counts.   Med: Median.   Max: Maximum.
* Case counts for reporting year 2010 are provisional and subject to change. For further information on interpretation of these data, see http://www.cdc.gov/ncphi/disss/nndss/phs/files/
ProvisionalNationa%20NotifiableDiseasesSurveillanceData20100927.pdf. Data for HIV/AIDS, AIDS and TB, when available, are displayed in Table IV, which appears quarterly.
† Contains data reported through the National Electronic Disease Surveillance System (NEDSS).
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TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending December 4, 2010, and December 5, 2009 (48th week)*
Reporting area
Meningococcal disease, invasive† 
All groups Pertussis Rabies, animal
Current 
week












Previous 52 weeks Cum 
2010
Cum 
2009Med Max Med Max Med Max
United States 6 15 43 695 881 353 373 1,756 18,586 14,235 41 64 143 3,102 4,822
New England — 0 3 18 33 1 8 23 449 596 — 4 15 211 321
Connecticut — 0 2 3 6 — 1 8 106 53 — 0 14 59 132
Maine§ — 0 1 4 4 1 1 5 45 80 — 1 4 58 51
Massachusetts — 0 2 6 15 — 5 14 239 337 — 0 0 — —
New Hampshire — 0 0 — 3 — 0 2 18 73 — 0 5 13 32
Rhode Island§ — 0 0 — 4 — 0 9 26 42 — 0 4 31 43
Vermont§ — 0 1 5 1 — 0 4 15 11 — 1 3 50 63
Mid. Atlantic 1 1 4 68 101 87 29 72 1,583 1,116 17 19 41 984 535
New Jersey — 0 2 17 17 — 3 9 132 230 — 0 0 — —
New York (Upstate) — 0 3 11 23 69 10 27 576 214 6 9 19 474 415
New York City — 0 2 16 17 — 0 9 78 88 — 2 12 120 20
Pennsylvania 1 0 2 24 44 18 11 54 797 584 11 8 24 390 100
E.N. Central — 2 9 118 159 87 90 174 4,657 2,951 — 2 27 223 218
Illinois — 0 3 19 44 — 15 29 778 603 — 1 11 114 82
Indiana — 0 3 24 34 — 9 26 504 359 — 0 0 — 25
Michigan — 0 3 21 20 7 27 55 1,305 809 — 1 5 64 65
Ohio — 1 2 31 40 80 28 71 1,626 1,015 — 0 12 45 46
Wisconsin — 0 3 23 21 — 8 21 444 165 — 0 0 — —
W.N. Central — 1 5 49 80 24 32 627 2,186 2,052 1 4 16 243 371
Iowa — 0 3 9 13 — 11 26 545 221 — 0 3 26 32
Kansas — 0 2 7 13 — 3 9 150 233 — 1 4 59 73
Minnesota — 0 2 2 13 — 0 601 698 421 — 0 9 26 60
Missouri — 0 4 24 26 23 8 43 508 969 — 1 6 66 65
Nebraska§ — 0 2 5 10 1 4 13 207 133 1 1 4 51 77
North Dakota — 0 1 2 1 — 0 30 50 29 — 0 7 15 11
South Dakota — 0 1 — 4 — 0 5 28 46 — 0 0 — 53
S. Atlantic 2 2 7 126 157 30 29 78 1,475 1,527 22 21 73 1,026 2,014
Delaware — 0 1 2 2 — 0 4 14 13 — 0 0 — —
District of Columbia — 0 0 — — — 0 1 7 6 — 0 0 — —
Florida 1 1 5 57 50 10 5 28 300 486 — 0 60 72 161
Georgia 1 0 2 13 30 1 3 18 220 217 — 0 8 — 387
Maryland§ — 0 1 8 10 1 3 8 124 140 5 6 14 344 368
North Carolina — 0 2 15 31 — 0 32 124 192 — 0 7 — 453
South Carolina§ — 0 1 10 11 9 5 19 328 247 — 0 0 — —
Virginia§ — 0 2 19 17 6 5 15 241 195 15 10 25 534 531
West Virginia — 0 2 2 6 3 1 21 117 31 2 1 7 76 114
E.S. Central — 1 3 39 33 6 15 34 690 761 — 3 7 139 136
Alabama§ — 0 1 7 10 — 4 8 179 288 — 1 4 49 —
Kentucky — 0 2 17 6 — 5 14 232 216 — 0 4 21 45
Mississippi — 0 1 5 3 2 1 8 71 74 — 0 1 1 4
Tennessee§ — 0 2 10 14 4 4 11 208 183 — 1 4 68 87
W.S. Central — 1 9 79 86 57 56 753 2,669 3,059 1 0 30 69 881
Arkansas§ — 0 1 6 9 — 3 29 159 329 — 0 7 28 38
Louisiana — 0 4 12 18 — 1 3 36 144 — 0 0 — —
Oklahoma — 0 7 15 14 23 0 41 89 75 1 0 30 41 32
Texas§ — 1 7 46 45 34 48 681 2,385 2,511 — 0 7 — 811
Mountain 1 1 6 51 60 27 27 92 1,465 933 — 1 8 80 103
Arizona — 0 2 13 13 — 7 16 379 250 — 0 5 — —
Colorado 1 0 4 20 21 25 4 86 437 208 — 0 0 — —
Idaho§ — 0 1 5 7 1 3 19 182 89 — 0 2 11 8
Montana§ — 0 1 1 5 — 1 12 82 56 — 0 3 17 25
Nevada§ — 0 1 8 4 — 0 7 32 24 — 0 2 8 6
New Mexico§ — 0 1 3 3 1 2 11 128 72 — 0 2 13 26
Utah — 0 1 1 2 — 4 13 215 212 — 0 2 10 13
Wyoming§ — 0 0 — 5 — 0 2 10 22 — 0 4 21 25
Pacific 2 3 16 147 172 34 43 209 3,412 1,240 — 3 12 127 243
Alaska — 0 1 1 6 — 0 6 38 55 — 0 2 12 12
California 1 2 13 98 108 17 28 181 2,625 646 — 2 12 102 220
Hawaii — 0 1 1 5 — 0 6 42 43 — 0 0 — —
Oregon 1 1 2 31 40 1 6 16 303 243 — 0 2 13 11
Washington — 0 7 16 13 16 5 38 404 253 — 0 0 — —
Territories
American Samoa — 0 0 — — — 0 0 — — N 0 0 N N
C.N.M.I. — — — — — — — — — — — — — — —
Guam — 0 0 — — — 0 0 — 2 — 0 0 — —
Puerto Rico — 0 0 — 1 — 0 1 3 1 — 1 3 40 39
U.S. Virgin Islands — 0 0 — — — 0 0 — — — 0 0 — —
C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable.   —: No reported cases.   N: Not reportable.   NN: Not Nationally Notifiable.   Cum: Cumulative year-to-date counts.   Med: Median.   Max: Maximum.
* Case counts for reporting year 2010 are provisional and subject to change. For further information on interpretation of these data, see http://www.cdc.gov/ncphi/disss/nndss/phs/files/
ProvisionalNationa%20NotifiableDiseasesSurveillanceData20100927.pdf. Data for HIV/AIDS, AIDS and TB, when available, are displayed in Table IV, which appears quarterly.
† Data for meningococcal disease, invasive caused by serogroups A, C, Y, and W-135; serogroup B; other serogroup; and unknown serogroup are available in Table I.
§ Contains data reported through the National Electronic Disease Surveillance System (NEDSS).
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TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending December 4, 2010, and December 5, 2009 (48th week)*
Reporting area
Salmonellosis Shiga toxin-producing E. coli (STEC)† Shigellosis
Current 
week












Previous 52 weeks Cum 
2010
Cum 
2009Med Max Med Max Med Max
United States 560 906 1,724 47,644 45,263 47 84 209 4,436 4,290 170 277 527 12,844 14,450
New England 3 32 476 2,115 2,070 — 2 52 187 286 — 4 66 295 327
Connecticut — 0 460 460 430 — 0 52 52 67 — 0 61 61 43
Maine§ 2 2 7 121 116 — 0 3 19 19 — 0 1 8 5
Massachusetts — 23 54 1,164 1,082 — 1 8 77 102 — 4 16 202 230
New Hampshire — 3 10 156 251 — 0 2 20 35 — 0 1 12 21
Rhode Island§ — 2 17 140 131 — 0 1 2 38 — 0 3 11 23
Vermont§ 1 1 5 74 60 — 0 2 17 25 — 0 1 1 5
Mid. Atlantic 29 95 219 5,392 5,155 5 9 31 499 407 4 34 53 1,461 2,631
New Jersey — 18 57 997 1,060 — 1 7 74 99 — 6 16 315 562
New York (Upstate) 16 25 78 1,342 1,220 4 3 13 190 141 3 4 19 212 207
New York City — 25 56 1,270 1,198 — 1 7 77 56 — 5 14 278 430
Pennsylvania 13 31 82 1,783 1,677 1 3 13 158 111 1 14 34 656 1,432
E.N. Central 27 88 245 5,039 4,877 — 9 39 692 689 4 27 238 1,555 2,377
Illinois — 28 114 1,693 1,393 — 2 9 121 164 — 9 228 760 577
Indiana — 11 62 622 586 — 1 9 67 93 — 1 5 38 68
Michigan 3 15 48 864 913 — 2 16 149 130 1 5 9 227 214
Ohio 24 24 47 1,246 1,337 — 3 11 136 124 3 6 23 289 1,040
Wisconsin — 10 45 614 648 — 3 17 219 178 — 4 21 241 478
W.N. Central 25 45 98 2,327 2,481 5 11 39 617 703 14 44 88 1,932 1,143
Iowa 5 9 34 499 378 — 2 16 165 154 — 1 5 47 51
Kansas 2 8 19 420 378 2 1 6 70 54 — 5 14 252 187
Minnesota — 0 32 178 529 — 0 13 31 204 — 0 3 14 74
Missouri 18 13 44 784 618 2 4 27 231 133 14 39 75 1,557 792
Nebraska§ — 4 13 237 330 1 1 6 71 83 — 1 10 55 31
North Dakota — 0 39 50 64 — 0 10 17 8 — 0 5 — 4
South Dakota — 3 15 159 184 — 0 4 32 67 — 0 2 7 4
S. Atlantic 233 268 609 14,799 13,392 19 13 30 698 632 39 46 127 2,507 2,229
Delaware 1 3 11 169 136 — 0 2 6 13 — 0 5 39 142
District of Columbia — 1 6 70 94 — 0 1 5 2 — 0 4 25 24
Florida 108 121 227 5,915 6,137 10 4 13 231 163 25 18 53 1,064 436
Georgia 40 41 132 2,618 2,263 — 1 15 103 68 7 14 39 725 619
Maryland§ 17 16 54 978 751 3 2 9 97 88 1 3 8 124 353
North Carolina 18 30 208 2,259 1,698 3 1 10 89 105 — 3 36 229 351
South Carolina§ 31 20 98 1,564 1,121 — 0 2 20 32 1 1 5 62 118
Virginia§ 11 18 68 1,056 985 3 2 15 126 132 4 2 15 136 177
West Virginia 7 2 16 170 207 — 0 4 21 29 1 0 66 103 9
E.S. Central 46 53 177 3,725 2,935 1 4 22 258 204 3 13 40 701 762
Alabama§ 9 19 52 992 877 — 1 4 51 45 2 3 14 200 147
Kentucky 14 10 31 548 426 — 1 6 68 67 1 3 28 212 209
Mississippi 10 17 67 1,175 876 — 0 12 30 6 — 1 4 51 47
Tennessee§ 13 14 53 1,010 756 1 2 7 109 86 — 5 14 238 359
W.S. Central 36 104 547 5,685 5,555 1 5 68 275 294 71 52 251 2,533 2,720
Arkansas§ 7 12 43 742 584 1 1 5 47 43 2 1 9 73 293
Louisiana 8 19 49 1,175 1,137 — 0 2 19 23 — 5 13 256 168
Oklahoma 8 12 46 638 580 — 0 27 40 32 2 6 96 250 267
Texas§ 13 51 477 3,130 3,254 — 3 41 169 196 67 41 144 1,954 1,992
Mountain 17 48 105 2,577 2,849 2 10 34 595 546 5 15 32 751 1,085
Arizona 1 17 42 878 1,018 — 1 11 82 65 2 8 18 409 778
Colorado 9 10 24 547 580 — 3 21 209 163 2 2 6 94 92
Idaho§ 4 3 9 156 165 1 2 7 101 88 — 0 3 23 8
Montana§ 2 2 7 84 103 1 1 5 40 35 — 0 1 6 11
Nevada§ 1 4 22 277 239 — 0 5 30 34 1 1 6 47 66
New Mexico§ — 6 18 309 347 — 1 5 41 36 — 2 10 132 103
Utah — 5 17 287 305 — 1 7 77 110 — 1 4 40 23
Wyoming§ — 1 5 39 92 — 0 2 15 15 — 0 0 — 4
Pacific 144 117 299 5,985 5,949 14 10 46 615 529 30 21 64 1,109 1,176
Alaska — 1 5 78 64 — 0 1 2 1 — 0 2 1 4
California 107 84 227 4,525 4,450 6 6 35 279 248 25 17 51 924 944
Hawaii 5 4 14 210 314 — 0 4 18 11 1 0 3 22 41
Oregon 1 8 48 487 408 1 2 15 113 78 — 1 5 57 51
Washington 31 14 61 685 713 7 2 19 203 191 4 1 20 105 136
Territories
American Samoa — 0 1 2 — — 0 0 — — — 1 1 4 3
C.N.M.I. — — — — — — — — — — — — — — —
Guam — 0 2 7 11 — 0 0 — — — 0 1 1 13
Puerto Rico 5 11 39 467 521 — 0 0 — — — 0 1 5 14
U.S. Virgin Islands — 0 0 — — — 0 0 — — — 0 0 — —
C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable.   —: No reported cases.   N: Not reportable.   NN: Not Nationally Notifiable.   Cum: Cumulative year-to-date counts.   Med: Median.   Max: Maximum.
* Case counts for reporting year 2010 are provisional and subject to change. For further information on interpretation of these data, see http://www.cdc.gov/ncphi/disss/nndss/phs/files/
ProvisionalNationa%20NotifiableDiseasesSurveillanceData20100927.pdf. Data for HIV/AIDS, AIDS and TB, when available, are displayed in Table IV, which appears quarterly.
† Includes E. coli O157:H7; Shiga toxin-positive, serogroup non-O157; and Shiga toxin-positive, not serogrouped.
§ Contains data reported through the National Electronic Disease Surveillance System (NEDSS).
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TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending December 4, 2010, and December 5, 2009 (48th week)*











Previous 52 weeks Cum  
2010
Cum  
2009Med Max Med Max
United States 1 2 12 155 143 8 23 421 1,450 1,226
New England — 0 0 — 2 — 0 1 3 11
Connecticut — 0 0 — — — 0 0 — —
Maine§ — 0 0 — — — 0 1 2 5
Massachusetts — 0 0 — 1 — 0 1 — 6
New Hampshire — 0 0 — — — 0 1 1 —
Rhode Island§ — 0 0 — — — 0 0 — —
Vermont§ — 0 0 — 1 — 0 0 — —
Mid. Atlantic — 0 2 16 12 1 1 4 59 95
New Jersey — 0 0 — 2 — 0 2 — 60
New York (Upstate) — 0 1 2 — 1 0 3 18 14
New York City — 0 1 1 1 — 0 4 28 7
Pennsylvania — 0 2 13 9 — 0 1 13 14
E.N. Central — 0 1 4 9 — 1 9 91 81
Illinois — 0 1 2 1 — 0 5 33 48
Indiana — 0 1 2 3 — 0 5 43 10
Michigan — 0 0 — 4 — 0 1 1 1
Ohio — 0 0 — — — 0 2 13 18
Wisconsin — 0 0 — 1 — 0 1 1 4
W.N. Central — 0 4 18 19 — 4 21 309 253
Iowa — 0 0 — 1 — 0 1 4 4
Kansas — 0 1 2 1 — 0 0 — —
Minnesota — 0 1 — 2 — 0 1 — 2
Missouri — 0 4 14 7 — 4 20 301 243
Nebraska§ — 0 1 2 8 — 0 1 3 4
North Dakota — 0 0 — — — 0 1 1 —
South Dakota — 0 0 — — — 0 0 — —
S. Atlantic 1 1 9 82 66 1 8 60 485 372
Delaware — 0 1 1 — — 0 3 20 18
District of Columbia — 0 1 1 — — 0 1 — —
Florida — 0 1 4 — — 0 2 11 7
Georgia 1 1 6 57 52 — 0 0 — —
Maryland§ — 0 1 3 3 — 1 5 53 37
North Carolina — 0 3 11 7 1 2 48 253 242
South Carolina§ — 0 1 1 3 — 0 2 18 15
Virginia§ — 0 2 4 1 — 2 12 130 51
West Virginia — 0 0 — — — 0 0 — 2
E.S. Central — 0 3 19 9 — 5 29 380 252
Alabama§ — 0 1 5 3 — 1 8 75 61
Kentucky — 0 2 6 1 — 0 0 — —
Mississippi — 0 0 — — — 0 3 15 9
Tennessee§ — 0 2 8 5 — 4 20 290 182
W.S. Central — 0 3 6 9 6 1 408 111 138
Arkansas§ — 0 2 2 — 6 0 110 64 70
Louisiana — 0 0 — — — 0 1 2 2
Oklahoma — 0 3 3 7 — 0 287 26 46
Texas§ — 0 1 1 2 — 0 11 19 20
Mountain — 0 1 2 16 — 0 2 12 24
Arizona — 0 1 — 10 — 0 1 2 12
Colorado — 0 0 — 1 — 0 1 1 —
Idaho§ — 0 0 — — — 0 1 5 1
Montana§ — 0 1 2 4 — 0 1 1 6
Nevada§ — 0 0 — — — 0 0 — 1
New Mexico§ — 0 0 — — — 0 1 1 1
Utah — 0 0 — — — 0 1 1 1
Wyoming§ — 0 0 — 1 — 0 1 1 2
Pacific — 0 2 8 1 — 0 0 — —
Alaska N 0 0 N N N 0 0 N N
California — 0 2 7 1 — 0 0 — —
Hawaii N 0 0 N N N 0 0 N N
Oregon — 0 1 1 — — 0 0 — —
Washington — 0 0 — — — 0 0 — —
Territories
American Samoa N 0 0 N N N 0 0 N N
C.N.M.I. — — — — — — — — — —
Guam N 0 0 N N N 0 0 N N
Puerto Rico N 0 0 N N N 0 0 N N
U.S. Virgin Islands — 0 0 — — — 0 0 — —
C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable.   —: No reported cases.   N: Not reportable.   NN: Not Nationally Notifiable.   Cum: Cumulative year-to-date counts.   Med: Median.   Max: Maximum.
* Case counts for reporting year 2010 are provisional and subject to change. For further information on interpretation of these data, see http://www.cdc.gov/ncphi/disss/nndss/phs/files/
ProvisionalNationa%20NotifiableDiseasesSurveillanceData20100927.pdf. Data for HIV/AIDS, AIDS and TB, when available, are displayed in Table IV, which appears quarterly.
† Illnesses with similar clinical presentation that result from Spotted fever group rickettsia infections are reported as Spotted fever rickettsioses. Rocky Mountain spotted fever (RMSF) caused 
by Rickettsia rickettsii, is the most common and well-known spotted fever.
§ Contains data reported through the National Electronic Disease Surveillance System (NEDSS).
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TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending December 4, 2010, and December 5, 2009 (48th week)*
Streptococcus pneumoniae,† invasive disease
Reporting area
All ages Age <5 Syphilis, primary and secondary
Current 
week












Previous 52 weeks Cum 
2010
Cum 
2009Med Max Med Max Med Max
United States 310 247 495 13,057 2,736 39 44 156 1,999 2,212 79 242 413 11,390 12,905
New England 30 9 99 706 50 2 1 24 90 71 4 9 22 428 299
Connecticut 23 0 91 336 — 1 0 22 28 — 2 1 10 87 53
Maine§ 2 2 6 110 19 — 0 1 10 8 — 0 3 23 3
Massachusetts — 1 5 58 3 — 1 4 40 44 — 5 15 257 214
New Hampshire — 0 7 59 — — 0 1 3 11 — 0 2 22 14
Rhode Island§ — 0 36 69 15 — 0 3 3 4 2 0 4 37 15
Vermont§ 5 1 6 74 13 1 0 1 6 4 — 0 2 2 —
Mid. Atlantic 28 26 56 1,268 189 15 7 48 341 278 12 33 46 1,550 1,635
New Jersey — 1 8 96 — — 1 5 50 60 6 4 12 219 207
New York (Upstate) 6 3 12 150 80 6 2 19 111 123 1 2 11 123 112
New York City 16 9 31 563 16 9 2 24 126 80 — 18 31 861 997
Pennsylvania 6 9 22 459 93 — 1 5 54 15 5 7 16 347 319
E.N. Central 56 49 98 2,658 622 2 7 18 328 382 1 27 49 1,248 1,438
Illinois — 2 7 95 — — 2 5 87 68 — 8 26 431 697
Indiana — 7 24 482 235 — 1 6 41 77 — 3 14 158 144
Michigan 4 12 27 630 25 — 1 6 75 72 — 4 12 196 217
Ohio 46 21 49 1,114 362 2 2 6 91 126 1 9 18 423 338
Wisconsin 6 6 22 337 — — 1 4 34 39 — 1 3 40 42
W.N. Central 11 10 182 699 168 1 2 12 122 172 1 6 18 315 286
Iowa — 0 0 — — — 0 0 — — — 0 3 16 21
Kansas 2 2 7 99 52 — 0 2 14 18 — 0 3 18 31
Minnesota — 0 179 287 43 — 0 10 44 81 1 2 9 131 65
Missouri 4 2 10 113 62 — 1 3 39 44 — 3 9 140 160
Nebraska§ 5 2 7 124 2 1 0 2 15 14 — 0 1 6 5
North Dakota — 0 11 60 7 — 0 1 2 5 — 0 0 — 4
South Dakota — 0 3 16 2 — 0 2 8 10 — 0 1 4 —
S. Atlantic 68 52 144 2,963 1,236 9 9 28 495 538 27 57 218 2,786 3,118
Delaware — 0 3 37 18 — 0 0 — 3 — 0 1 4 27
District of Columbia — 0 4 24 20 — 0 2 7 5 — 2 21 145 161
Florida 39 23 89 1,340 702 7 3 18 182 187 1 21 44 1,009 965
Georgia 10 11 28 511 395 2 3 12 143 158 4 12 167 600 751
Maryland§ 9 7 31 457 4 — 1 6 48 76 3 6 14 284 282
North Carolina — 0 0 — — — 0 0 — — 10 7 22 332 532
South Carolina§ 9 6 25 430 — — 1 4 46 46 2 2 7 137 114
Virginia§ — 1 4 49 — — 1 4 47 44 7 4 22 270 282
West Virginia 1 2 21 115 97 — 0 4 22 19 — 0 2 5 4
E.S. Central 26 21 50 1,175 248 — 2 8 114 139 — 16 39 782 1,046
Alabama§ — 0 0 — — — 0 0 — — — 5 11 220 401
Kentucky 5 3 16 181 70 — 0 2 13 8 — 2 13 120 62
Mississippi — 1 6 51 51 — 0 2 11 25 — 4 17 200 201
Tennessee§ 21 18 44 943 127 — 2 6 90 106 — 5 17 242 382
W.S. Central 51 28 91 1,697 111 5 5 41 263 323 21 37 63 1,772 2,602
Arkansas§ 1 3 9 150 51 — 0 3 16 39 2 3 12 162 262
Louisiana 1 2 8 99 60 — 0 3 25 29 3 8 28 396 709
Oklahoma 2 1 5 44 — 2 1 5 44 55 — 1 7 77 86
Texas§ 47 23 83 1,404 — 3 3 34 178 200 16 24 34 1,137 1,545
Mountain 37 29 82 1,626 109 4 4 12 214 280 2 10 25 475 495
Arizona 12 11 51 705 — 2 2 7 90 115 — 3 8 148 219
Colorado 22 10 20 517 — 2 1 4 63 45 — 3 8 127 91
Idaho§ 1 0 2 16 — — 0 2 9 9 — 0 1 2 3
Montana§ 1 0 2 21 — — 0 1 3 — — 0 2 3 4
Nevada§ 1 2 4 75 38 — 0 1 5 7 — 1 9 111 88
New Mexico§ — 2 9 139 — — 0 4 16 36 2 1 4 48 58
Utah — 2 9 142 59 — 0 3 25 66 — 1 4 36 29
Wyoming§ — 0 1 11 12 — 0 1 3 2 — 0 0 — 3
Pacific 3 5 14 265 3 1 0 7 32 29 11 42 61 2,034 1,986
Alaska — 2 9 102 — — 0 5 19 19 — 0 1 1 —
California 3 3 12 163 — 1 0 2 13 — 6 36 54 1,750 1,774
Hawaii — 0 0 — 3 — 0 0 — 10 — 0 4 32 33
Oregon — 0 0 — — — 0 0 — — 1 1 7 59 49
Washington — 0 0 — — — 0 0 — — 4 4 11 192 130
Territories
American Samoa — 0 0 — — — 0 0 — — — 0 0 — —
C.N.M.I. — — — — — — — — — — — — — — —
Guam — 0 0 — — — 0 0 — — — 0 0 — —
Puerto Rico — 0 0 — — — 0 0 — — — 4 15 202 200
U.S. Virgin Islands — 0 0 — — — 0 0 — — — 0 0 — —
C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable.   —: No reported cases.   N: Not reportable.   NN: Not Nationally Notifiable.   Cum: Cumulative year-to-date counts.   Med: Median.   Max: Maximum.
* Case counts for reporting year 2010 are provisional and subject to change. For further information on interpretation of these data, see http://www.cdc.gov/ncphi/disss/nndss/phs/files/
ProvisionalNationa%20NotifiableDiseasesSurveillanceData20100927.pdf. Data for HIV/AIDS, AIDS and TB, when available, are displayed in Table IV, which appears quarterly.
† Includes drug resistant and susceptible cases of invasive Streptococcus pneumoniae disease among children <5 years and among all ages. Case definition: Isolation of S. pneumoniae from 
a normally sterile body site (e.g., blood or cerebrospinal fluid).
§ Contains data reported through the National Electronic Disease Surveillance System (NEDSS).
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TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending December 4, 2010, and December 5, 2009 (48th week)*
West Nile virus disease†
Reporting area
Varicella (chickenpox)§ Neuroinvasive Nonneuroinvasive¶
Current 
week












Previous 52 weeks Cum 
2010
Cum 
2009Med Max Med Max Med Max
United States 261 292 550 13,227 19,250 — 0 70 595 384 — 1 52 377 334
New England 11 14 36 699 1,027 — 0 3 13 — — 0 1 2 —
Connecticut 2 6 20 288 468 — 0 2 6 — — 0 1 1 —
Maine§ — 4 15 213 228 — 0 0 — — — 0 0 — —
Massachusetts — 0 1 2 4 — 0 2 6 — — 0 1 1 —
New Hampshire — 2 8 114 191 — 0 1 1 — — 0 0 — —
Rhode Island§ — 1 12 32 39 — 0 0 — — — 0 0 — —
Vermont§ 9 0 10 50 97 — 0 0 — — — 0 0 — —
Mid. Atlantic 38 33 62 1,513 1,937 — 0 19 125 9 — 0 13 62 1
New Jersey — 8 30 498 442 — 0 3 15 3 — 0 6 15 —
New York (Upstate) N 0 0 N N — 0 9 57 3 — 0 7 30 1
New York City — 0 0 — — — 0 7 32 3 — 0 4 8 —
Pennsylvania 38 22 39 1,015 1,495 — 0 3 21 — — 0 3 9 —
E.N. Central 74 100 176 4,434 6,076 — 0 14 75 9 — 0 7 28 4
Illinois 5 22 45 1,108 1,514 — 0 10 41 5 — 0 4 15 —
Indiana§ 15 6 35 389 421 — 0 2 5 2 — 0 2 6 2
Michigan 22 31 62 1,338 1,782 — 0 6 25 1 — 0 1 4 —
Ohio 27 29 56 1,264 1,805 — 0 1 4 — — 0 1 1 2
Wisconsin 5 6 22 335 554 — 0 0 — 1 — 0 1 2 —
W.N. Central 15 15 32 762 1,220 — 0 7 28 26 — 0 11 68 75
Iowa N 0 0 N N — 0 1 2 — — 0 2 4 5
Kansas§ — 4 22 228 528 — 0 1 3 4 — 0 2 10 9
Minnesota — 0 0 — — — 0 1 4 1 — 0 3 4 3
Missouri 15 7 23 442 557 — 0 1 3 4 — 0 0 — 1
Nebraska§ N 0 0 N N — 0 3 10 11 — 0 7 27 41
North Dakota — 0 9 37 83 — 0 2 2 — — 0 2 7 1
South Dakota — 1 7 55 52 — 0 2 4 6 — 0 3 16 15
S. Atlantic 39 34 100 1,985 2,443 — 0 4 33 16 — 0 4 21 2
Delaware§ — 0 3 24 12 — 0 0 — — — 0 0 — —
District of Columbia — 0 4 18 30 — 0 1 1 2 — 0 1 1 —
Florida§ 25 15 57 946 1,077 — 0 2 8 2 — 0 1 3 1
Georgia N 0 0 N N — 0 1 4 4 — 0 3 8 —
Maryland§ N 0 0 N N — 0 3 16 — — 0 2 7 1
North Carolina N 0 0 N N — 0 0 — — — 0 0 — —
South Carolina§ — 0 35 75 123 — 0 1 1 3 — 0 0 — —
Virginia§ 8 11 34 495 723 — 0 1 3 5 — 0 1 2 —
West Virginia 6 8 26 427 478 — 0 0 — — — 0 0 — —
E.S. Central 4 5 22 278 519 — 0 1 8 36 — 0 3 11 27
Alabama§ 4 5 22 271 514 — 0 1 1 — — 0 1 2 —
Kentucky N 0 0 N N — 0 1 2 3 — 0 1 1 —
Mississippi — 0 2 7 5 — 0 1 3 29 — 0 2 6 22
Tennessee§ N 0 0 N N — 0 1 2 4 — 0 2 2 5
W.S. Central 69 45 285 2,562 4,644 — 0 15 97 117 — 0 3 19 35
Arkansas§ — 2 32 129 465 — 0 3 6 6 — 0 1 1 —
Louisiana — 2 5 80 129 — 0 3 14 10 — 0 1 6 11
Oklahoma N 0 0 N N — 0 0 — 8 — 0 0 — 2
Texas§ 69 39 272 2,353 4,050 — 0 15 77 93 — 0 2 12 22
Mountain 9 20 36 927 1,290 — 0 18 151 77 — 0 15 127 123
Arizona — 0 0 — — — 0 13 103 12 — 0 9 58 8
Colorado§ 8 8 18 379 497 — 0 5 26 36 — 0 11 55 67
Idaho§ N 0 0 N N — 0 0 — 9 — 0 1 3 29
Montana§ — 3 17 182 161 — 0 0 — 2 — 0 0 — 3
Nevada§ N 0 0 N N — 0 0 — 7 — 0 1 2 5
New Mexico§ 1 1 8 92 113 — 0 5 19 6 — 0 2 4 2
Utah — 5 17 260 519 — 0 1 1 1 — 0 1 1 1
Wyoming§ — 0 3 14 — — 0 1 2 4 — 0 1 4 8
Pacific 2 1 6 67 94 — 0 7 65 94 — 0 5 39 67
Alaska — 0 5 37 55 — 0 0 — — — 0 0 — —
California — 0 0 — — — 0 7 64 67 — 0 5 38 45
Hawaii 2 0 6 30 39 — 0 0 — — — 0 0 — —
Oregon N 0 0 N N — 0 0 — 1 — 0 0 — 10
Washington N 0 0 N N — 0 1 1 26 — 0 1 1 12
Territories
American Samoa N 0 0 N N — 0 0 — — — 0 0 — —
C.N.M.I. — — — — — — — — — — — — — — —
Guam — 0 2 15 30 — 0 0 — — — 0 0 — —
Puerto Rico 1 9 30 518 488 — 0 0 — — — 0 0 — —
U.S. Virgin Islands — 0 0 — — — 0 0 — — — 0 0 — —
C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable.   —: No reported cases.   N: Not reportable.   NN: Not Nationally Notifiable.   Cum: Cumulative year-to-date counts.   Med: Median.   Max: Maximum.
* Case counts for reporting year 2010 are provisional and subject to change. For further information on interpretation of these data, see http://www.cdc.gov/ncphi/disss/nndss/phs/files/
ProvisionalNationa%20NotifiableDiseasesSurveillanceData20100927.pdf. Data for HIV/AIDS, AIDS and TB, when available, are displayed in Table IV, which appears quarterly.
† Updated weekly from reports to the Division of Vector-Borne Infectious Diseases, National Center for Zoonotic, Vector-Borne, and Enteric Diseases (ArboNET Surveillance). Data for California 
serogroup, eastern equine, Powassan, St. Louis, and western equine diseases are available in Table I.
§ Contains data reported through the National Electronic Disease Surveillance System (NEDSS).
¶ Not reportable in all states. Data from states where the condition is not reportable are excluded from this table, except starting in 2007 for the domestic arboviral diseases and influenza-
associated pediatric mortality, and in 2003 for SARS-CoV. Reporting exceptions are available at http://www.cdc.gov/ncphi/disss/nndss/phs/infdis.htm.
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TABLE III. Deaths in 122 U.S. cities,* week ending December 4, 2010 (48th week)
Reporting area
All causes, by age (years)
P&I† 
Total Reporting area




Ages ≥65 45–64 25–44 1–24 <1
All  
Ages ≥65 45–64 25–44 1–24 <1
New England 638 455 136 35 7 5 62 S. Atlantic 1,375 907 334 85 25 24 86
Boston, MA 152 96 44 8 2 2 14 Atlanta, GA 147 107 29 7 3 1 7
Bridgeport, CT 26 23 2 1 — — 3 Baltimore, MD 172 97 54 13 5 3 12
Cambridge, MA 31 26 5 — — — 2 Charlotte, NC 156 103 34 13 2 4 14
Fall River, MA 41 36 4 1 — — 3 Jacksonville, FL 167 117 35 11 2 2 11
Hartford, CT 66 46 13 4 2 1 9 Miami, FL 113 70 30 7 5 1 3
Lowell, MA 22 11 5 5 — 1 3 Norfolk, VA 56 36 15 4 — 1 2
Lynn, MA 14 11 2 1 — — 1 Richmond, VA 48 32 11 5 — — 5
New Bedford, MA 34 24 9 1 — — 2 Savannah, GA 59 43 13 1 1 1 6
New Haven, CT 50 31 13 5 — 1 4 St. Petersburg, FL 57 44 11 1 1 — 3
Providence, RI 83 62 17 3 1 — 7 Tampa, FL 276 177 70 17 4 8 15
Somerville, MA 4 2 1 1 — — — Washington, D.C. 104 66 28 6 1 3 7
Springfield, MA 16 9 4 2 1 — 4 Wilmington, DE 20 15 4 — 1 — 1
Waterbury, CT 28 23 5 — — — 2 E.S. Central 945 611 222 55 29 27 73
Worcester, MA 71 55 12 3 1 — 8 Birmingham, AL 229 146 54 11 9 8 16
Mid. Atlantic 2,028 1,433 426 110 32 25 97 Chattanooga, TN 76 53 13 7 — 3 6
Albany, NY 49 35 13 1 — — 1 Knoxville, TN 121 79 34 6 1 1 9
Allentown, PA 27 24 3 — — — 1 Lexington, KY 61 42 16 1 2 — 5
Buffalo, NY 69 45 15 4 4 1 4 Memphis, TN 186 118 44 13 7 4 14
Camden, NJ 3 2 1 — — — — Mobile, AL 91 60 21 6 1 3 7
Elizabeth, NJ 17 13 4 — — — 1 Montgomery, AL 28 21 4 1 1 1 7
Erie, PA 63 49 13 — — 1 9 Nashville, TN 153 92 36 10 8 7 9
Jersey City, NJ 28 18 5 4 1 — 2 W.S. Central 1,393 905 334 89 33 31 79
New York City, NY 961 697 203 40 11 9 41 Austin, TX 115 71 32 7 5 — 7
Newark, NJ 29 13 8 7 1 — — Baton Rouge, LA 80 47 15 13 — 5 —
Paterson, NJ 27 19 4 3 — 1 3 Corpus Christi, TX 65 43 17 1 4 — 8
Philadelphia, PA 364 233 77 32 11 11 9 Dallas, TX 303 180 83 22 9 8 17
Pittsburgh, PA§ 37 26 9 1 — 1 5 El Paso, TX 111 86 19 4 1 1 1
Reading, PA 36 27 6 2 — — 1 Fort Worth, TX U U U U U U U
Rochester, NY 81 56 16 6 3 — 4 Houston, TX 89 56 18 3 5 7 6
Schenectady, NY 27 19 8 — — — 2 Little Rock, AR 79 49 24 4 1 1 —
Scranton, PA 26 23 3 — — — — New Orleans, LA U U U U U U U
Syracuse, NY 103 80 20 1 1 1 10 San Antonio, TX 295 205 58 21 5 6 23
Trenton, NJ 48 29 14 5 — — 2 Shreveport, LA 89 55 28 4 1 1 6
Utica, NY 13 12 1 — — — — Tulsa, OK 167 113 40 10 2 2 11
Yonkers, NY 20 13 3 4 — — 2 Mountain 1,205 798 280 73 32 22 66
E.N. Central 2,139 1,482 472 113 38 34 131 Albuquerque, NM 148 98 38 6 5 1 9
Akron, OH 79 56 15 5 1 2 3 Boise, ID 76 54 10 8 4 — 5
Canton, OH 28 22 4 2 — — 2 Colorado Springs, CO 85 54 19 9 1 2 1
Chicago, IL 207 131 57 15 4 — 13 Denver, CO 76 41 27 4 1 3 1
Cincinnati, OH 99 62 19 12 2 4 5 Las Vegas, NV 235 167 52 10 4 2 11
Cleveland, OH 295 206 70 15 3 1 15 Ogden, UT 42 29 10 2 — 1 2
Columbus, OH 219 150 52 8 4 5 14 Phoenix, AZ 192 115 49 15 8 5 12
Dayton, OH 164 115 44 4 — 1 12 Pueblo, CO 42 33 5 2 2 — 4
Detroit, MI 194 114 59 13 7 1 10 Salt Lake City, UT 149 100 34 5 4 6 10
Evansville, IN 51 39 9 2 — 1 5 Tucson, AZ 160 107 36 12 3 2 11
Fort Wayne, IN 76 56 14 2 3 1 — Pacific 1,879 1,328 397 87 35 32 154
Gary, IN 7 4 2 — 1 — — Berkeley, CA 17 10 6 — — 1 —
Grand Rapids, MI 50 38 8 1 2 1 1 Fresno, CA 158 113 33 8 2 2 22
Indianapolis, IN 170 128 28 6 — 8 12 Glendale, CA 38 30 8 — — — 2
Lansing, MI 72 56 11 3 1 1 4 Honolulu, HI 79 60 12 4 — 3 8
Milwaukee, WI 108 70 26 6 5 1 9 Long Beach, CA 47 33 11 — 2 1 6
Peoria, IL 59 43 11 2 2 1 4 Los Angeles, CA 296 195 68 18 7 8 32
Rockford, IL 71 47 17 7 — — 8 Pasadena, CA 32 25 3 2 1 1 5
South Bend, IN 74 53 12 4 2 3 5 Portland, OR 107 84 16 5 1 1 6
Toledo, OH 59 43 7 6 1 2 6 Sacramento, CA 303 210 70 11 8 4 28
Youngstown, OH 57 49 7 — — 1 3 San Diego, CA 27 20 6 1 — — 2
W.N. Central 697 456 179 32 16 12 48 San Francisco, CA 118 74 31 6 4 3 8
Des Moines, IA 12 11 1 — — — — San Jose, CA 244 185 46 7 3 3 14
Duluth, MN 31 29 1 1 — — 5 Santa Cruz, CA 44 34 8 1 1 — 2
Kansas City, KS 45 22 21 1 1 — 5 Seattle, WA 132 82 31 13 2 4 2
Kansas City, MO 106 69 32 3 1 1 5 Spokane, WA 84 65 13 4 1 1 7
Lincoln, NE 49 36 11 1 1 — 2 Tacoma, WA 153 108 35 7 3 — 10
Minneapolis, MN 76 47 20 3 4 2 5 Total¶ 12,299 8,375 2,780 679 247 212 796
Omaha, NE 96 71 19 4 1 1 11
St. Louis, MO 135 70 39 12 7 5 8
St. Paul, MN 61 44 13 3 — 1 3
Wichita, KS 86 57 22 4 1 2 4
U: Unavailable.   —: No reported cases.   
* Mortality data in this table are voluntarily reported from 122 cities in the United States, most of which have populations of >100,000. A death is reported by the place of its occurrence and 
by the week that the death certificate was filed. Fetal deaths are not included.
† Pneumonia and influenza.
§ Because of changes in reporting methods in this Pennsylvania city, these numbers are partial counts for the current week. Complete counts will be available in 4 to 6 weeks.
¶ Total includes unknown ages.
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